-
1
-
-
84955299344
-
Global cancer incidence and mortality rates and trends—An update
-
Torre, L.A.; Siegel, R.L.; Ward, E.M.; Jemal, A. Global cancer incidence and mortality rates and trends—An update. Cancer Epidemiol. Biomark. Prev. 2016, 25, 16–27. [CrossRef] [PubMed]
-
(2016)
Cancer Epidemiol. Biomark. Prev.
, vol.25
, pp. 16-27
-
-
Torre, L.A.1
Siegel, R.L.2
Ward, E.M.3
Jemal, A.4
-
2
-
-
7044264264
-
Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study
-
Davila, J.A.; Morgan, R.O.; Shaib, Y.; McGlynn, K.A.; El-Serag, H.B. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study. Gastroenterology 2004, 127, 1372–1380. [CrossRef] [PubMed]
-
(2004)
Gastroenterology
, vol.127
, pp. 1372-1380
-
-
Davila, J.A.1
Morgan, R.O.2
Shaib, Y.3
McGlynn, K.A.4
El-Serag, H.B.5
-
3
-
-
79959361853
-
Factors that affect risk for hepatocellular carcinoma and effects of surveillance
-
Yang, J.D.; Harmsen, W.S.; Slettedahl, S.W.; Chaiteerakij, R.; Enders, F.T.; Therneau, T.M.; Orsini, L.; Kim, W.R.; Roberts, L.R. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin. Gastroenterol. Hepatol. 2011, 9, 617–623. [CrossRef] [PubMed]
-
(2011)
Clin. Gastroenterol. Hepatol.
, vol.9
, pp. 617-623
-
-
Yang, J.D.1
Harmsen, W.S.2
Slettedahl, S.W.3
Chaiteerakij, R.4
Enders, F.T.5
Therneau, T.M.6
Orsini, L.7
Kim, W.R.8
Roberts, L.R.9
-
4
-
-
0023933449
-
Hepatitis B virus. The major etiology of hepatocellular carcinoma
-
Beasley, R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61, 1942–1956. [CrossRef]
-
(1988)
Cancer
, vol.61
, pp. 1942-1956
-
-
Beasley, R.P.1
-
5
-
-
0028818446
-
Primary prevention of hepatocellular carcinoma
-
Yu, S.Z. Primary prevention of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1995, 10, 674–682. [CrossRef] [PubMed]
-
(1995)
J. Gastroenterol. Hepatol.
, vol.10
, pp. 674-682
-
-
Yu, S.Z.1
-
6
-
-
0031914318
-
Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice
-
Ghebranious, N.; Sell, S. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology 1998, 27, 383–391. [CrossRef] [PubMed]
-
(1998)
Hepatology
, vol.27
, pp. 383-391
-
-
Ghebranious, N.1
Sell, S.2
-
7
-
-
0141891303
-
Habitual betel quid chewing as a risk factor for cirrhosis: A case-control study
-
Tsai, J.F.; Jeng, J.E.; Chuang, L.Y.; Ho, M.S.; Ko, Y.C.; Lin, Z.Y.; Hsieh, M.Y.; Chen, S.C.; Chuang, W.L.; Wang, L.Y.; et al. Habitual betel quid chewing as a risk factor for cirrhosis: A case-control study. Medicine 2003, 82, 365–372. [CrossRef] [PubMed]
-
(2003)
Medicine
, vol.82
, pp. 365-372
-
-
Tsai, J.F.1
Jeng, J.E.2
Chuang, L.Y.3
Ho, M.S.4
Ko, Y.C.5
Lin, Z.Y.6
Hsieh, M.Y.7
Chen, S.C.8
Chuang, W.L.9
Wang, L.Y.10
-
8
-
-
0035793805
-
Betel quid chewing as a risk factor for hepatocellular carcinoma: A case-control study
-
Tsai, J.F.; Chuang, L.Y.; Jeng, J.E.; Ho, M.S.; Hsieh, M.Y.; Lin, Z.Y.; Wang, L.Y. Betel quid chewing as a risk factor for hepatocellular carcinoma: A case-control study. Br. J. Cancer 2001, 84, 709–713. [CrossRef] [PubMed]
-
(2001)
Br. J. Cancer
, vol.84
, pp. 709-713
-
-
Tsai, J.F.1
Chuang, L.Y.2
Jeng, J.E.3
Ho, M.S.4
Hsieh, M.Y.5
Lin, Z.Y.6
Wang, L.Y.7
-
9
-
-
85019705576
-
Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers
-
Chu, Y.J.; Yang, H.I.; Wu, H.C.; Liu, J.; Wang, L.Y.; Lu, S.N.; Lee, M.H.; Jen, C.L.; You, S.L.; Santella, R.M.; et al. Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. Int. J. Cancer 2017, 141, 711–720. [CrossRef] [PubMed]
-
(2017)
Int. J. Cancer
, vol.141
, pp. 711-720
-
-
Chu, Y.J.1
Yang, H.I.2
Wu, H.C.3
Liu, J.4
Wang, L.Y.5
Lu, S.N.6
Lee, M.H.7
Jen, C.L.8
You, S.L.9
Santella, R.M.10
-
10
-
-
0025828517
-
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
-
Bressac, B.; Kew, M.; Wands, J.; Ozturk, M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350, 429–431. [CrossRef] [PubMed]
-
(1991)
Nature
, vol.350
, pp. 429-431
-
-
Bressac, B.1
Kew, M.2
Wands, J.3
Ozturk, M.4
-
11
-
-
0027952779
-
Genetic heterogeneity of hepatocellular carcinoma
-
Unsal, H.; Yakicier, C.; Marcais, C.; Kew, M.; Volkmann, M.; Zentgraf, H.; Isselbacher, K.J.; Ozturk, M. Genetic heterogeneity of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 1994, 91, 822–826. [CrossRef] [PubMed]
-
(1994)
Proc. Natl. Acad. Sci. USA
, vol.91
, pp. 822-826
-
-
Unsal, H.1
Yakicier, C.2
Marcais, C.3
Kew, M.4
Volkmann, M.5
Zentgraf, H.6
Isselbacher, K.J.7
Ozturk, M.8
-
12
-
-
0029916475
-
Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1
-
Yan, R.Q.; Su, J.J.; Huang, D.R.; Gan, Y.C.; Yang, C.; Huang, G.H. Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1. J. Cancer Res. Clin. Oncol. 1996, 122, 289–295. [CrossRef] [PubMed]
-
(1996)
J. Cancer Res. Clin. Oncol.
, vol.122
, pp. 289-295
-
-
Yan, R.Q.1
Su, J.J.2
Huang, D.R.3
Gan, Y.C.4
Yang, C.5
Huang, G.H.6
-
13
-
-
84944906098
-
Functional and genetic deconstruction of the cellular origin in liver cancer
-
Marquardt, J.U.; Andersen, J.B.; Thorgeirsson, S.S. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat. Rev. Cancer 2015, 15, 653–667. [CrossRef] [PubMed]
-
(2015)
Nat. Rev. Cancer
, vol.15
, pp. 653-667
-
-
Marquardt, J.U.1
Andersen, J.B.2
Thorgeirsson, S.S.3
-
14
-
-
84938799837
-
Toward understanding and exploiting tumor heterogeneity
-
Alizadeh, A.A.; Aranda, V.; Bardelli, A.; Blanpain, C.; Bock, C.; Borowski, C.; Caldas, C.; Califano, A.; Doherty, M.; Elsner, M.; et al. Toward understanding and exploiting tumor heterogeneity. Nat. Med. 2015, 21, 846–853. [CrossRef] [PubMed]
-
(2015)
Nat. Med.
, vol.21
, pp. 846-853
-
-
Alizadeh, A.A.1
Aranda, V.2
Bardelli, A.3
Blanpain, C.4
Bock, C.5
Borowski, C.6
Caldas, C.7
Califano, A.8
Doherty, M.9
Elsner, M.10
-
15
-
-
84929129284
-
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
-
Schulze, K. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 2015, 47, 505–511. [CrossRef] [PubMed]
-
(2015)
Nat. Genet
, vol.47
, pp. 505-511
-
-
Schulze, K.1
-
16
-
-
84861625981
-
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
-
Guichard, C.; Amaddeo, G.; Imbeaud, S.; Ladeiro, Y.; Pelletier, L.; Maad, I.B.; Calderaro, J.; Bioulac-Sage, P.; Letexier, M.; Degos, F.; et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012, 44, 694–698. [CrossRef] [PubMed]
-
(2012)
Nat. Genet.
, vol.44
, pp. 694-698
-
-
Guichard, C.1
Amaddeo, G.2
Imbeaud, S.3
Ladeiro, Y.4
Pelletier, L.5
Maad, I.B.6
Calderaro, J.7
Bioulac-Sage, P.8
Letexier, M.9
Degos, F.10
-
17
-
-
79955090518
-
Telomerase gene mutations are associated with cirrhosis formation
-
Hartmann, D.; Srivastava, U.; Thaler, M.; Kleinhans, K.N.; N’Kontchou, G.; Scheffold, A.; Bauer, K.; Kratzer, R.F.; Kloos, N.; Katz, S.F.; et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology 2011, 53, 1608–1617. [CrossRef] [PubMed]
-
(2011)
Hepatology
, vol.53
, pp. 1608-1617
-
-
Hartmann, D.1
Srivastava, U.2
Thaler, M.3
Kleinhans, K.N.4
N’Kontchou, G.5
Scheffold, A.6
Bauer, K.7
Kratzer, R.F.8
Kloos, N.9
Katz, S.F.10
-
18
-
-
79955119666
-
Constitutional telomerase mutations are genetic risk factors for cirrhosis
-
Calado, R.T.; Brudno, J.; Mehta, P.; Kovacs, J.J.; Wu, C.; Zago, M.A.; Chanock, S.J.; Boyer, T.D.; Young, N.S. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology 2011, 53, 1600–1607. [CrossRef] [PubMed]
-
(2011)
Hepatology
, vol.53
, pp. 1600-1607
-
-
Calado, R.T.1
Brudno, J.2
Mehta, P.3
Kovacs, J.J.4
Wu, C.5
Zago, M.A.6
Chanock, S.J.7
Boyer, T.D.8
Young, N.S.9
-
19
-
-
0034681457
-
Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery
-
Rudolph, K.L.; Chang, S.; Millard, M.; Schreiber-Agus, N.; DePinho, R.A. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000, 287, 1253–1258. [CrossRef] [PubMed]
-
(2000)
Science
, vol.287
, pp. 1253-1258
-
-
Rudolph, K.L.1
Chang, S.2
Millard, M.3
Schreiber-Agus, N.4
Depinho, R.A.5
-
20
-
-
34248177482
-
Telomerase activation in liver regeneration and hepatocarcinogenesis: Dr. Jekyll or Mr. Hyde?
-
Wege, H.; Brummendorf, T.H. Telomerase activation in liver regeneration and hepatocarcinogenesis: Dr. Jekyll or Mr. Hyde? Curr. Stem Cell Res. Ther. 2007, 2, 31–38. [CrossRef] [PubMed]
-
(2007)
Curr. Stem Cell Res. Ther.
, vol.2
, pp. 31-38
-
-
Wege, H.1
Brummendorf, T.H.2
-
21
-
-
18444374159
-
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis
-
Wiemann, S.U.; Satyanarayana, A.; Tsahuridu, M.; Tillmann, H.L.; Zender, L.; Klempnauer, J.; Flemming, P.; Franco, S.; Blasco, M.A.; Manns, M.P.; et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 2002, 16, 935–942. [CrossRef] [PubMed]
-
(2002)
FASEB J
, vol.16
, pp. 935-942
-
-
Wiemann, S.U.1
Satyanarayana, A.2
Tsahuridu, M.3
Tillmann, H.L.4
Zender, L.5
Klempnauer, J.6
Flemming, P.7
Franco, S.8
Blasco, M.A.9
Manns, M.P.10
-
22
-
-
0042440603
-
Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma
-
Farazi, P.A.; Glickman, J.; Jiang, S.; Yu, A.; Rudolph, K.L.; DePinho, R.A. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res. 2003, 63, 5021–5027. [PubMed]
-
(2003)
Cancer Res
, vol.63
, pp. 5021-5027
-
-
Farazi, P.A.1
Glickman, J.2
Jiang, S.3
Yu, A.4
Rudolph, K.L.5
Depinho, R.A.6
-
23
-
-
84911902519
-
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis
-
Nault, J.C.; Calderaro, J.; Di Tommaso, L.; Balabaud, C.; Zafrani, E.S.; Bioulac-Sage, P.; Roncalli, M.; Zucman-Rossi, J. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 2014, 60, 1983–1992. [CrossRef] [PubMed]
-
(2014)
Hepatology
, vol.60
, pp. 1983-1992
-
-
Nault, J.C.1
Calderaro, J.2
Di Tommaso, L.3
Balabaud, C.4
Zafrani, E.S.5
Bioulac-Sage, P.6
Roncalli, M.7
Zucman-Rossi, J.8
-
24
-
-
84901472677
-
Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification
-
Ahn, S.M.; Jang, S.J.; Shim, J.H.; Kim, D.; Hong, S.M.; Sung, C.O.; Baek, D.; Haq, F.; Ansari, A.A.; Lee, S.Y.; et al. Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 2014, 60, 1972–1982. [CrossRef] [PubMed]
-
(2014)
Hepatology
, vol.60
, pp. 1972-1982
-
-
Ahn, S.M.1
Jang, S.J.2
Shim, J.H.3
Kim, D.4
Hong, S.M.5
Sung, C.O.6
Baek, D.7
Haq, F.8
Ansari, A.A.9
Lee, S.Y.10
-
25
-
-
84881436148
-
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
-
Nault, J.C.; Mallet, M.; Pilati, C.; Calderaro, J.; Bioulac-Sage, P.; Laurent, C.; Laurent, A.; Cherqui, D.; Balabaud, C.; Zucman-Rossi, J. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 2013, 4, 2218. [CrossRef] [PubMed]
-
(2013)
Nat. Commun
, vol.4
-
-
Nault, J.C.1
Mallet, M.2
Pilati, C.3
Calderaro, J.4
Bioulac-Sage, P.5
Laurent, C.6
Laurent, A.7
Cherqui, D.8
Balabaud, C.9
Zucman-Rossi, J.10
-
26
-
-
0042968962
-
Molecular viral oncology of hepatocellular carcinoma
-
Block, T.M.; Mehta, A.S.; Fimmel, C.J.; Jordan, R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22, 5093–5107. [CrossRef] [PubMed]
-
(2003)
Oncogene
, vol.22
, pp. 5093-5107
-
-
Block, T.M.1
Mehta, A.S.2
Fimmel, C.J.3
Jordan, R.4
-
27
-
-
0026335594
-
Chromosome deletions associated with hepatitis B virus integration
-
Tokino, T.; Tamura, H.; Hori, N.; Matsubara, K. Chromosome deletions associated with hepatitis B virus integration. Virology 1991, 185, 879–882. [CrossRef]
-
(1991)
Virology
, vol.185
, pp. 879-882
-
-
Tokino, T.1
Tamura, H.2
Hori, N.3
Matsubara, K.4
-
28
-
-
22644435919
-
Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas
-
Murakami, Y.; Saigo, K.; Takashima, H.; Minami, M.; Okanoue, T.; Brechot, C.; Paterlini-Brechot, P. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005, 54, 1162–1168. [CrossRef] [PubMed]
-
(2005)
Gut
, vol.54
, pp. 1162-1168
-
-
Murakami, Y.1
Saigo, K.2
Takashima, H.3
Minami, M.4
Okanoue, T.5
Brechot, C.6
Paterlini-Brechot, P.7
-
29
-
-
0035860752
-
Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes
-
Tarn, C.; Lee, S.; Hu, Y.; Ashendel, C.; Andrisani, O.M. Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J. Biol. Chem. 2001, 276, 34671–34680. [CrossRef] [PubMed]
-
(2001)
J. Biol. Chem.
, vol.276
, pp. 34671-34680
-
-
Tarn, C.1
Lee, S.2
Hu, Y.3
Ashendel, C.4
Andrisani, O.M.5
-
30
-
-
0034785734
-
Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo
-
Nijhara, R.; Jana, S.S.; Goswami, S.K.; Rana, A.; Majumdar, S.S.; Kumar, V.; Sarkar, D.P. Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo. J. Virol. 2001, 75, 10348–10358. [CrossRef] [PubMed]
-
(2001)
J. Virol.
, vol.75
, pp. 10348-10358
-
-
Nijhara, R.1
Jana, S.S.2
Goswami, S.K.3
Rana, A.4
Majumdar, S.S.5
Kumar, V.6
Sarkar, D.P.7
-
31
-
-
0035943513
-
An internal segment (Residues 58–119) of the hepatitis B virus X protein is sufficient to activate MAP kinase pathways in mouse liver
-
Nijhara, R.; Jana, S.S.; Goswami, S.K.; Kumar, V.; Sarkar, D.P. An internal segment (residues 58–119) of the hepatitis B virus X protein is sufficient to activate MAP kinase pathways in mouse liver. FEBS Lett. 2001, 504, 59–64. [CrossRef]
-
(2001)
FEBS Lett
, vol.504
, pp. 59-64
-
-
Nijhara, R.1
Jana, S.S.2
Goswami, S.K.3
Kumar, V.4
Sarkar, D.P.5
-
32
-
-
0037061766
-
Genetic mechanisms of hepatocarcinogenesis
-
Feitelson, M.A.; Sun, B.; Satiroglu Tufan, N.L.; Liu, J.; Pan, J.; Lian, Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002, 21, 2593–2604. [CrossRef] [PubMed]
-
(2002)
Oncogene
, vol.21
, pp. 2593-2604
-
-
Feitelson, M.A.1
Sun, B.2
Satiroglu Tufan, N.L.3
Liu, J.4
Pan, J.5
Lian, Z.6
-
33
-
-
0033058294
-
Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein
-
Yu, D.Y.; Moon, H.B.; Son, J.K.; Jeong, S.; Yu, S.L.; Yoon, H.; Han, Y.M.; Lee, C.S.; Park, J.S.; Lee, C.H.; et al. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J. Hepatol. 1999, 31, 123–132. [CrossRef]
-
(1999)
J. Hepatol.
, vol.31
, pp. 123-132
-
-
Yu, D.Y.1
Moon, H.B.2
Son, J.K.3
Jeong, S.4
Yu, S.L.5
Yoon, H.6
Han, Y.M.7
Lee, C.S.8
Park, J.S.9
Lee, C.H.10
-
34
-
-
0025907983
-
HBx gene of hepatitis B virus induces liver cancer in transgenic mice
-
Kim, C.-M.; Koike, K.; Saito, I.; Miyamura, T.; Jay, G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991, 351, 317–320. [CrossRef] [PubMed]
-
(1991)
Nature
, vol.351
, pp. 317-320
-
-
Kim, C.-M.1
Koike, K.2
Saito, I.3
Miyamura, T.4
Jay, G.5
-
35
-
-
2342588229
-
Genomic analysis of the host response to hepatitis B virus infection
-
Wieland, S.; Thimme, R.; Purcell, R.H.; Chisari, F.V. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 2004, 101, 6669–6674. [CrossRef] [PubMed]
-
(2004)
Proc. Natl. Acad. Sci. USA
, vol.101
, pp. 6669-6674
-
-
Wieland, S.1
Thimme, R.2
Purcell, R.H.3
Chisari, F.V.4
-
36
-
-
14944375587
-
Immunology of hepatitis B virus and hepatitis C virus infection
-
Rehermann, B.; Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 2005, 5, 215–229. [CrossRef] [PubMed]
-
(2005)
Nat. Rev. Immunol.
, vol.5
, pp. 215-229
-
-
Rehermann, B.1
Nascimbeni, M.2
-
37
-
-
33747830764
-
Hepatocellular carcinoma pathogenesis: From genes to environment
-
Farazi, P.A.; DePinho, R.A. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat. Rev. Immunol. 2006, 6, 674–687. [CrossRef] [PubMed]
-
(2006)
Nat. Rev. Immunol.
, vol.6
, pp. 674-687
-
-
Farazi, P.A.1
Depinho, R.A.2
-
38
-
-
23944476834
-
Unravelling hepatitis C virus replication from genome to function
-
Lindenbach, B.D.; Rice, C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436, 933–938. [CrossRef] [PubMed]
-
(2005)
Nature
, vol.436
, pp. 933-938
-
-
Lindenbach, B.D.1
Rice, C.M.2
-
39
-
-
23044437222
-
Complete replication of hepatitis C virus in cell culture
-
Lindenbach, B.D.; Evans, M.J.; Syder, A.J.; Wolk, B.; Tellinghuisen, T.L.; Liu, C.C.; Maruyama, T.; Hynes, R.O.; Burton, D.R.; McKeating, J.A.; et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309, 623–626. [CrossRef] [PubMed]
-
(2005)
Science
, vol.309
, pp. 623-626
-
-
Lindenbach, B.D.1
Evans, M.J.2
Syder, A.J.3
Wolk, B.4
Tellinghuisen, T.L.5
Liu, C.C.6
Maruyama, T.7
Hynes, R.O.8
Burton, D.R.9
McKeating, J.A.10
-
40
-
-
22544470874
-
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
-
Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, A.; Krausslich, H.G.; Mizokami, M.; et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11, 791–796. [CrossRef] [PubMed]
-
(2005)
Nat. Med.
, vol.11
, pp. 791-796
-
-
Wakita, T.1
Pietschmann, T.2
Kato, T.3
Date, T.4
Miyamoto, M.5
Zhao, Z.6
Murthy, K.7
Habermann, A.8
Krausslich, H.G.9
Mizokami, M.10
-
41
-
-
84954417122
-
Targeting Wnt/beta-catenin pathway in hepatocellular carcinoma treatment
-
Vilchez, V.; Turcios, L.; Marti, F.; Gedaly, R. Targeting Wnt/beta-catenin pathway in hepatocellular carcinoma treatment. World J. Gastroenterol. 2016, 22, 823–832. [CrossRef] [PubMed]
-
(2016)
World J. Gastroenterol.
, vol.22
, pp. 823-832
-
-
Vilchez, V.1
Turcios, L.2
Marti, F.3
Gedaly, R.4
-
42
-
-
1642535593
-
Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations
-
Harada, N.; Oshima, H.; Katoh, M.; Tamai, Y.; Oshima, M.; Taketo, M.M. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res. 2004, 64, 48–54. [CrossRef] [PubMed]
-
(2004)
Cancer Res
, vol.64
, pp. 48-54
-
-
Harada, N.1
Oshima, H.2
Katoh, M.3
Tamai, Y.4
Oshima, M.5
Taketo, M.M.6
-
43
-
-
84861986053
-
Wnt/beta-catenin signaling and disease
-
Clevers, H.; Nusse, R. Wnt/beta-catenin signaling and disease. Cell 2012, 149, 1192–1205. [CrossRef] [PubMed]
-
(2012)
Cell
, vol.149
, pp. 1192-1205
-
-
Clevers, H.1
Nusse, R.2
-
44
-
-
33645457576
-
Constitutive activation of NF-kappaB in human hepatocellular carcinoma: Evidence of a cytoprotective role
-
Qiao, L.; Zhang, H.; Yu, J.; Francisco, R.; Dent, P.; Ebert, M.P.; Rocken, C.; Farrell, G. Constitutive activation of NF-kappaB in human hepatocellular carcinoma: Evidence of a cytoprotective role. Hum. Gene Ther. 2006, 17, 280–290. [CrossRef] [PubMed]
-
(2006)
Hum. Gene Ther.
, vol.17
, pp. 280-290
-
-
Qiao, L.1
Zhang, H.2
Yu, J.3
Francisco, R.4
Dent, P.5
Ebert, M.P.6
Rocken, C.7
Farrell, G.8
-
45
-
-
70349308534
-
Mechanisms of liver disease: Cross-talk between the NF-kappaB and JNK pathways
-
Papa, S.; Bubici, C.; Zazzeroni, F.; Franzoso, G. Mechanisms of liver disease: Cross-talk between the NF-kappaB and JNK pathways. Biol. Chem. 2009, 390, 965–976. [CrossRef] [PubMed]
-
(2009)
Biol. Chem.
, vol.390
, pp. 965-976
-
-
Papa, S.1
Bubici, C.2
Zazzeroni, F.3
Franzoso, G.4
-
46
-
-
36549036709
-
A cell cycle regulatory network controlling NF-kappaB subunit activity and function
-
Barre, B.; Perkins, N.D. A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J. 2007, 26, 4841–4855. [CrossRef] [PubMed]
-
(2007)
EMBO J
, vol.26
, pp. 4841-4855
-
-
Barre, B.1
Perkins, N.D.2
-
47
-
-
80051677812
-
P53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-kappaB
-
Johnson, R.F.; Witzel, I.I.; Perkins, N.D. p53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-kappaB. Cancer Res. 2011, 71, 5588–5597. [CrossRef] [PubMed]
-
(2011)
Cancer Res
, vol.71
, pp. 5588-5597
-
-
Johnson, R.F.1
Witzel, I.I.2
Perkins, N.D.3
-
48
-
-
85114281005
-
Glycolysis inhibition as a strategy for hepatocellular carcinoma treatment?
-
Alves, A.; Mamede, A.C.; Alves, M.; Oliveira, P.F.; Rocha, S.M.; Botelho, F.; Maia, C.J. Glycolysis inhibition as a strategy for hepatocellular carcinoma treatment? Curr. Cancer Drug Targets 2018. [CrossRef] [PubMed]
-
(2018)
Curr. Cancer Drug Targets
-
-
Alves, A.1
Mamede, A.C.2
Alves, M.3
Oliveira, P.F.4
Rocha, S.M.5
Botelho, F.6
Maia, C.J.7
-
49
-
-
84971280382
-
FLIP(L) is critical for aerobic glycolysis in hepatocellular carcinoma
-
Lei, S.; Yang, J.; Chen, C.; Sun, J.; Yang, L.; Tang, H.; Yang, T.; Chen, A.; Zhao, H.; Li, Y.; et al. FLIP(L) is critical for aerobic glycolysis in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2016, 35, 79. [CrossRef] [PubMed]
-
(2016)
J. Exp. Clin. Cancer Res.
, vol.35
, pp. 79
-
-
Lei, S.1
Yang, J.2
Chen, C.3
Sun, J.4
Yang, L.5
Tang, H.6
Yang, T.7
Chen, A.8
Zhao, H.9
Li, Y.10
-
50
-
-
85027460324
-
Molecular machineries of pH dysregulation in tumor microenvironment: Potential targets for cancer therapy
-
Asgharzadeh, M.R.; Barar, J.; Pourseif, M.M.; Eskandani, M.; Jafari Niya, M.; Mashayekhi, M.R.; Omidi, Y. Molecular machineries of pH dysregulation in tumor microenvironment: Potential targets for cancer therapy. Bioimpacts 2017, 7, 115–133. [CrossRef] [PubMed]
-
(2017)
Bioimpacts
, vol.7
, pp. 115-133
-
-
Asgharzadeh, M.R.1
Barar, J.2
Pourseif, M.M.3
Eskandani, M.4
Jafari Niya, M.5
Mashayekhi, M.R.6
Omidi, Y.7
-
51
-
-
84870376274
-
N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells
-
Kretzmann, N.A.; Chiela, E.; Matte, U.; Marroni, N.; Marroni, C.A. N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells. Comp. Hepatol. 2012, 11, 4. [CrossRef] [PubMed]
-
(2012)
Comp. Hepatol.
, vol.11
, pp. 4
-
-
Kretzmann, N.A.1
Chiela, E.2
Matte, U.3
Marroni, N.4
Marroni, C.A.5
-
52
-
-
79951829343
-
Hypoxia and inflammation
-
Eltzschig, H.K.; Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 2011, 364, 656–665. [CrossRef] [PubMed]
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 656-665
-
-
Eltzschig, H.K.1
Carmeliet, P.2
-
53
-
-
70249099576
-
Interdependence of hypoxic and innate immune responses
-
Nizet, V.; Johnson, R.S. Interdependence of hypoxic and innate immune responses. Nat. Rev. Immunol. 2009, 9, 609–617. [CrossRef] [PubMed]
-
(2009)
Nat. Rev. Immunol.
, vol.9
, pp. 609-617
-
-
Nizet, V.1
Johnson, R.S.2
-
54
-
-
85041503582
-
Tumor hypoxia as an enhancer of inflammation-mediated metastasis: Emerging therapeutic strategies
-
DiGiacomo, J.W.; Gilkes, D.M. Tumor hypoxia as an enhancer of inflammation-mediated metastasis: Emerging therapeutic strategies. Target. Oncol. 2018, 13, 157–173. [CrossRef] [PubMed]
-
(2018)
Target. Oncol.
, vol.13
, pp. 157-173
-
-
Digiacomo, J.W.1
Gilkes, D.M.2
-
55
-
-
84871789026
-
Restriction of intestinal stem cell expansion and the regenerative response by YAP
-
Barry, E.R.; Morikawa, T.; Butler, B.L.; Shrestha, K.; de la Rosa, R.; Yan, K.S.; Fuchs, C.S.; Magness, S.T.; Smits, R.; Ogino, S.; et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013, 493, 106–110. [CrossRef] [PubMed]
-
(2013)
Nature
, vol.493
, pp. 106-110
-
-
Barry, E.R.1
Morikawa, T.2
Butler, B.L.3
Shrestha, K.4
de la Rosa, R.5
Yan, K.S.6
Fuchs, C.S.7
Magness, S.T.8
Smits, R.9
Ogino, S.10
-
56
-
-
85040645899
-
YAP-associated chromosomal instability and cholangiocarcinoma in mice
-
Rizvi, S.; Fischbach, S.R.; Bronk, S.F.; Hirsova, P.; Krishnan, A.; Dhanasekaran, R.; Smadbeck, J.B.; Smoot, R.L.; Vasmatzis, G.; Gores, G.J. YAP-associated chromosomal instability and cholangiocarcinoma in mice. Oncotarget 2018, 9, 5892–5905. [CrossRef] [PubMed]
-
(2018)
Oncotarget
, vol.9
, pp. 5892-5905
-
-
Rizvi, S.1
Fischbach, S.R.2
Bronk, S.F.3
Hirsova, P.4
Krishnan, A.5
Dhanasekaran, R.6
Smadbeck, J.B.7
Smoot, R.L.8
Vasmatzis, G.9
Gores, G.J.10
-
57
-
-
84955270341
-
An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression
-
Hayashi, H.; Higashi, T.; Yokoyama, N.; Kaida, T.; Sakamoto, K.; Fukushima, Y.; Ishimoto, T.; Kuroki, H.; Nitta, H.; Hashimoto, D.; et al. An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. Cancer Res. 2015, 75, 4985–4997. [CrossRef] [PubMed]
-
(2015)
Cancer Res
, vol.75
, pp. 4985-4997
-
-
Hayashi, H.1
Higashi, T.2
Yokoyama, N.3
Kaida, T.4
Sakamoto, K.5
Fukushima, Y.6
Ishimoto, T.7
Kuroki, H.8
Nitta, H.9
Hashimoto, D.10
-
58
-
-
84980018556
-
Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma
-
Wu, H.; Liu, Y.; Jiang, X.W.; Li, W.F.; Guo, G.; Gong, J.P.; Ding, X. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma. Tumor Biol. 2016, 37, 13499–13508. [CrossRef] [PubMed]
-
(2016)
Tumor Biol
, vol.37
, pp. 13499-13508
-
-
Wu, H.1
Liu, Y.2
Jiang, X.W.3
Li, W.F.4
Guo, G.5
Gong, J.P.6
Ding, X.7
-
59
-
-
36549074631
-
YAP1 increases organ size and expands undifferentiated progenitor cells
-
Camargo, F.D.; Gokhale, S.; Johnnidis, J.B.; Fu, D.; Bell, G.W.; Jaenisch, R.; Brummelkamp, T.R. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 2007, 17, 2054–2060. [CrossRef] [PubMed]
-
(2007)
Curr. Biol.
, vol.17
, pp. 2054-2060
-
-
Camargo, F.D.1
Gokhale, S.2
Johnnidis, J.B.3
Fu, D.4
Bell, G.W.5
Jaenisch, R.6
Brummelkamp, T.R.7
-
60
-
-
84884291548
-
Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2
-
Yin, F.; Yu, J.; Zheng, Y.; Chen, Q.; Zhang, N.; Pan, D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 2013, 154, 1342–1355. [CrossRef] [PubMed]
-
(2013)
Cell
, vol.154
, pp. 1342-1355
-
-
Yin, F.1
Yu, J.2
Zheng, Y.3
Chen, Q.4
Zhang, N.5
Pan, D.6
-
61
-
-
0034092011
-
Tumor angiogenesis: Past, present and the near future
-
Kerbel, R.S. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000, 21, 505–515. [CrossRef] [PubMed]
-
(2000)
Carcinogenesis
, vol.21
, pp. 505-515
-
-
Kerbel, R.S.1
-
62
-
-
84925286958
-
Tissue expression, serum and salivary levels of vascular endothelial growth factor in patients with HNSCC
-
Andisheh-Tadbir, A.; Hamzavi, M.; Rezvani, G.; Ashraf, M.J.; Fattahi, M.J.; Khademi, B.; Kamali, F. Tissue expression, serum and salivary levels of vascular endothelial growth factor in patients with HNSCC. Braz. J. Otorhinolaryngol. 2014, 80, 503–507. [CrossRef] [PubMed]
-
(2014)
Braz. J. Otorhinolaryngol.
, vol.80
, pp. 503-507
-
-
Andisheh-Tadbir, A.1
Hamzavi, M.2
Rezvani, G.3
Ashraf, M.J.4
Fattahi, M.J.5
Khademi, B.6
Kamali, F.7
-
63
-
-
84991795131
-
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases
-
360ra135. [CrossRef] [PubMed
-
Rahbari, N.N.; Kedrin, D.; Incio, J.; Liu, H.; Ho, W.W.; Nia, H.T.; Edrich, C.M.; Jung, K.; Daubriac, J.; Chen, I.; et al. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Sci. Transl. Med. 2016, 8, 360ra135. [CrossRef] [PubMed]
-
(2016)
Sci. Transl. Med.
, vol.8
-
-
Rahbari, N.N.1
Kedrin, D.2
Incio, J.3
Liu, H.4
Ho, W.W.5
Nia, H.T.6
Edrich, C.M.7
Jung, K.8
Daubriac, J.9
Chen, I.10
-
64
-
-
84984876330
-
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
-
Yang, Y.; Zhang, Y.; Iwamoto, H.; Hosaka, K.; Seki, T.; Andersson, P.; Lim, S.; Fischer, C.; Nakamura, M.; Abe, M.; et al. Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism. Nat. Commun. 2016, 7, 12680. [CrossRef] [PubMed]
-
(2016)
Nat. Commun.
, vol.7
-
-
Yang, Y.1
Zhang, Y.2
Iwamoto, H.3
Hosaka, K.4
Seki, T.5
Andersson, P.6
Lim, S.7
Fischer, C.8
Nakamura, M.9
Abe, M.10
-
65
-
-
84862650711
-
Low VEGF expression in conceptus material and maternal serum AFP and beta-hCG levels as indicators of defective angiogenesis in first-trimester miscarriages
-
Kutluer, G.; Cicek, N.M.; Moraloglu, O.; Ertargin, P.; Sarikaya, E.; Artar, I.; Erdem, O. Low VEGF expression in conceptus material and maternal serum AFP and beta-hCG levels as indicators of defective angiogenesis in first-trimester miscarriages. J. Turk. Ger. Gynecol. Assoc. 2012, 13, 111–117. [PubMed]
-
(2012)
J. Turk. Ger. Gynecol. Assoc.
, vol.13
, pp. 111-117
-
-
Kutluer, G.1
Cicek, N.M.2
Moraloglu, O.3
Ertargin, P.4
Sarikaya, E.5
Artar, I.6
Erdem, O.7
-
66
-
-
84966480845
-
Thrombosis recanalization by paeoniflorin through the upregulation of urokinasetype plasminogen activator via the MAPK signaling pathway
-
Ye, S.; Mao, B.; Yang, L.; Fu, W.; Hou, J. Thrombosis recanalization by paeoniflorin through the upregulation of urokinasetype plasminogen activator via the MAPK signaling pathway. Mol. Med. Rep. 2016, 13, 4593–4598. [CrossRef] [PubMed]
-
(2016)
Mol. Med. Rep.
, vol.13
, pp. 4593-4598
-
-
Ye, S.1
Mao, B.2
Yang, L.3
Fu, W.4
Hou, J.5
-
67
-
-
85041660436
-
Urokinase type plasminogen activator and the molecular mechanisms of its regulation in cancer
-
Santibanez, J.F. Urokinase type plasminogen activator and the molecular mechanisms of its regulation in cancer. Protein Pept. Lett. 2017, 24, 936–946. [CrossRef] [PubMed]
-
(2017)
Protein Pept. Lett
, vol.24
, pp. 936-946
-
-
Santibanez, J.F.1
-
68
-
-
85028026897
-
Urokinase-type plasminogen activator receptor (UPAR) expression enhances invasion and metastasis in RAS mutated tumors
-
Mauro, C.D.; Pesapane, A.; Formisano, L.; Rosa, R.; D’Amato, V.; Ciciola, P.; Servetto, A.; Marciano, R.; Orsini, R.C.; Monteleone, F.; et al. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci. Rep. 2017, 7, 9388. [CrossRef] [PubMed]
-
(2017)
Sci. Rep.
, vol.7
-
-
Mauro, C.D.1
Pesapane, A.2
Formisano, L.3
Rosa, R.4
D’Amato, V.5
Ciciola, P.6
Servetto, A.7
Marciano, R.8
Orsini, R.C.9
Monteleone, F.10
-
69
-
-
84984918509
-
UPA/uPAR and SERPINE1 in head and neck cancer: Role in tumor resistance, metastasis, prognosis and therapy
-
Pavon, M.A.; Arroyo-Solera, I.; Cespedes, M.V.; Casanova, I.; Leon, X.; Mangues, R. uPA/uPAR and SERPINE1 in head and neck cancer: Role in tumor resistance, metastasis, prognosis and therapy. Oncotarget 2016, 7, 57351–57366. [CrossRef] [PubMed]
-
(2016)
Oncotarget
, vol.7
, pp. 57351-57366
-
-
Pavon, M.A.1
Arroyo-Solera, I.2
Cespedes, M.V.3
Casanova, I.4
Leon, X.5
Mangues, R.6
-
70
-
-
85014307140
-
Tumor budding, uPA, and PAI-1 in colorectal cancer: Update of a prospective study
-
Markl, B.; Hardt, J.; Franz, S.; Schaller, T.; Schenkirsch, G.; Kriening, B.; Hoffmann, R.; Ruth, S. Tumor budding, uPA, and PAI-1 in colorectal cancer: Update of a prospective study. Gastroenterol. Res. Pract. 2017, 2017, 6504960. [CrossRef] [PubMed]
-
(2017)
Gastroenterol. Res. Pract.
, vol.2017
-
-
Markl, B.1
Hardt, J.2
Franz, S.3
Schaller, T.4
Schenkirsch, G.5
Kriening, B.6
Hoffmann, R.7
Ruth, S.8
-
71
-
-
84859203369
-
Expression of urokinase-type plasminogen activator (UPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance
-
Andres, S.A.; Edwards, A.B.; Wittliff, J.L. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance. J. Clin. Lab. Anal. 2012, 26, 93–103. [CrossRef] [PubMed]
-
(2012)
J. Clin. Lab. Anal.
, vol.26
, pp. 93-103
-
-
Andres, S.A.1
Edwards, A.B.2
Wittliff, J.L.3
-
72
-
-
85018510367
-
Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas
-
Rubina, K.A.; Sysoeva, V.Y.; Zagorujko, E.I.; Tsokolaeva, Z.I.; Kurdina, M.I.; Parfyonova, Y.V.; Tkachuk, V.A. Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas. Arch. Dermatol. Res. 2017, 309, 433–442. [CrossRef] [PubMed]
-
(2017)
Arch. Dermatol. Res.
, vol.309
, pp. 433-442
-
-
Rubina, K.A.1
Sysoeva, V.Y.2
Zagorujko, E.I.3
Tsokolaeva, Z.I.4
Kurdina, M.I.5
Parfyonova, Y.V.6
Tkachuk, V.A.7
-
73
-
-
84896975948
-
Role of uPA/uPAR in the modulation of angiogenesis
-
PubMed
-
Montuori, N.; Ragno, P. Role of uPA/uPAR in the modulation of angiogenesis. Chem. Immunol. Allergy 2014, 99, 105–122. [PubMed]
-
(2014)
Chem. Immunol. Allergy
, vol.99
, pp. 105-122
-
-
Montuori, N.1
Ragno, P.2
-
74
-
-
79952674668
-
Targeting integrins in hepatocellular carcinoma
-
Wu, Y.; Qiao, X.; Qiao, S.; Yu, L. Targeting integrins in hepatocellular carcinoma. Expert Opin. Ther. Targets 2011, 15, 421–437. [CrossRef] [PubMed]
-
(2011)
Expert Opin. Ther. Targets
, vol.15
, pp. 421-437
-
-
Wu, Y.1
Qiao, X.2
Qiao, S.3
Yu, L.4
-
76
-
-
84918586280
-
Integrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma
-
Soejima, Y.; Inoue, M.; Takahashi, Y.; Uozaki, H.; Sawabe, M.; Fukusato, T. Integrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma. Hepatol. Res. 2014, 44, 320–334. [CrossRef] [PubMed]
-
(2014)
Hepatol. Res.
, vol.44
, pp. 320-334
-
-
Soejima, Y.1
Inoue, M.2
Takahashi, Y.3
Uozaki, H.4
Sawabe, M.5
Fukusato, T.6
-
77
-
-
84929519112
-
Integrins mediate the migration of HepG2 cells induced by low shear stress
-
PubMed
-
Lijuan, W.; Liu, X.; Yu, H.; Zhou, F.; Chen, H.; Liu, Q. Integrins mediate the migration of HepG2 cells induced by low shear stress. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2014, 31, 336–340. [PubMed]
-
(2014)
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
, vol.31
, pp. 336-340
-
-
Lijuan, W.1
Liu, X.2
Yu, H.3
Zhou, F.4
Chen, H.5
Liu, Q.6
-
78
-
-
85044821162
-
Beta1 integrin-mediated multicellular resistance in hepatocellular carcinoma through activation of the FAK/Akt pathway
-
Tian, T.; Li, C.L.; Fu, X.; Wang, S.H.; Lu, J.; Guo, H.; Yao, Y.; Nan, K.J.; Yang, Y.J. beta1 integrin-mediated multicellular resistance in hepatocellular carcinoma through activation of the FAK/Akt pathway. J. Int. Med. Res. 2018, 46, 1311–1325. [CrossRef] [PubMed]
-
(2018)
J. Int. Med. Res
, vol.46
, pp. 1311-1325
-
-
Tian, T.1
Li, C.L.2
Fu, X.3
Wang, S.H.4
Lu, J.5
Guo, H.6
Yao, Y.7
Nan, K.J.8
Yang, Y.J.9
-
79
-
-
85030254883
-
Cross-talk mechanism between endothelial cells and hepatocellular carcinoma cells via growth factors and integrin pathway promotes tumor angiogenesis and cell migration
-
Feng, T.; Yu, H.; Xia, Q.; Ma, Y.; Yin, H.; Shen, Y.; Liu, X. Cross-talk mechanism between endothelial cells and hepatocellular carcinoma cells via growth factors and integrin pathway promotes tumor angiogenesis and cell migration. Oncotarget 2017, 8, 69577–69593. [CrossRef] [PubMed]
-
(2017)
Oncotarget
, vol.8
, pp. 69577-69593
-
-
Feng, T.1
Yu, H.2
Xia, Q.3
Ma, Y.4
Yin, H.5
Shen, Y.6
Liu, X.7
-
80
-
-
85049476805
-
Farnesoid X receptor activation enhances transforming growth factor beta-induced epithelial-mesenchymal transition in hepatocellular carcinoma cells
-
Kainuma, M.; Takada, I.; Makishima, M.; Sano, K. Farnesoid X receptor activation enhances transforming growth factor beta-induced epithelial-mesenchymal transition in hepatocellular carcinoma cells. Int. J. Mol. Sci. 2018, 19, 1898. [CrossRef] [PubMed]
-
(2018)
Int. J. Mol. Sci.
, vol.19
, pp. 1898
-
-
Kainuma, M.1
Takada, I.2
Makishima, M.3
Sano, K.4
-
81
-
-
33645821043
-
Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration
-
Huang, W.; Ma, K.; Zhang, J.; Qatanani, M.; Cuvillier, J.; Liu, J.; Dong, B.; Huang, X.; Moore, D.D. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006, 312, 233–236. [CrossRef] [PubMed]
-
(2006)
Science
, vol.312
, pp. 233-236
-
-
Huang, W.1
Ma, K.2
Zhang, J.3
Qatanani, M.4
Cuvillier, J.5
Liu, J.6
Dong, B.7
Huang, X.8
Moore, D.D.9
-
82
-
-
84920409241
-
FXR and liver carcinogenesis
-
Huang, X.F.; Zhao, W.Y.; Huang, W.D. FXR and liver carcinogenesis. Acta Pharmacol. Sin. 2015, 36, 37–43. [CrossRef] [PubMed]
-
(2015)
Acta Pharmacol. Sin.
, vol.36
, pp. 37-43
-
-
Huang, X.F.1
Zhao, W.Y.2
Huang, W.D.3
-
83
-
-
84867305638
-
FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model
-
Deuschle, U.; Schuler, J.; Schulz, A.; Schluter, T.; Kinzel, O.; Abel, U.; Kremoser, C. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS ONE 2012, 7, e43044. [CrossRef] [PubMed]
-
(2012)
Plos ONE
, vol.7
-
-
Deuschle, U.1
Schuler, J.2
Schulz, A.3
Schluter, T.4
Kinzel, O.5
Abel, U.6
Kremoser, C.7
-
84
-
-
33847044019
-
Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor
-
Yang, F.; Huang, X.; Yi, T.; Yen, Y.; Moore, D.D.; Huang, W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007, 67, 863–867. [CrossRef] [PubMed]
-
(2007)
Cancer Res
, vol.67
, pp. 863-867
-
-
Yang, F.1
Huang, X.2
Yi, T.3
Yen, Y.4
Moore, D.D.5
Huang, W.6
-
85
-
-
84870888675
-
Critical role of farnesoid X receptor for hepatocellular carcinoma cell proliferation
-
Fujino, T.; Takeuchi, A.; Maruko-Ohtake, A.; Ohtake, Y.; Satoh, J.; Kobayashi, T.; Tanaka, T.; Ito, H.; Sakamaki, R.; Kashimura, R.; et al. Critical role of farnesoid X receptor for hepatocellular carcinoma cell proliferation. J. Biochem. 2012, 152, 577–586. [CrossRef] [PubMed]
-
(2012)
J. Biochem.
, vol.152
, pp. 577-586
-
-
Fujino, T.1
Takeuchi, A.2
Maruko-Ohtake, A.3
Ohtake, Y.4
Satoh, J.5
Kobayashi, T.6
Tanaka, T.7
Ito, H.8
Sakamaki, R.9
Kashimura, R.10
-
86
-
-
34447098081
-
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
-
Kim, I.; Morimura, K.; Shah, Y.; Yang, Q.; Ward, J.M.; Gonzalez, F.J. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007, 28, 940–946. [CrossRef] [PubMed]
-
(2007)
Carcinogenesis
, vol.28
, pp. 940-946
-
-
Kim, I.1
Morimura, K.2
Shah, Y.3
Yang, Q.4
Ward, J.M.5
Gonzalez, F.J.6
-
87
-
-
85010671909
-
Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis
-
Niu, Y.; Xu, M.; Slagle, B.L.; Huang, H.; Li, S.; Guo, G.L.; Shi, G.; Qin, W.; Xie, W. Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis. Hepatology 2017, 65, 893–906. [CrossRef] [PubMed]
-
(2017)
Hepatology
, vol.65
, pp. 893-906
-
-
Niu, Y.1
Xu, M.2
Slagle, B.L.3
Huang, H.4
Li, S.5
Guo, G.L.6
Shi, G.7
Qin, W.8
Xie, W.9
-
88
-
-
85019538507
-
Hepatocellular carcinoma
-
Llovet, J.M.; Zucman-Rossi, J.; Pikarsky, E.; Sangro, B.; Schwartz, M.; Sherman, M.; Gores, G. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 2016, 2, 16018. [CrossRef] [PubMed]
-
(2016)
Nat. Rev. Dis. Prim.
, vol.2
-
-
Llovet, J.M.1
Zucman-Rossi, J.2
Pikarsky, E.3
Sangro, B.4
Schwartz, M.5
Sherman, M.6
Gores, G.7
-
89
-
-
48249153424
-
Apoptosis and hepatic necroinflammation
-
Gores, G.J. Apoptosis and hepatic necroinflammation. Gastroenterol. Hepatol. 2008, 4, 394–395.
-
(2008)
Gastroenterol. Hepatol.
, vol.4
, pp. 394-395
-
-
Gores, G.J.1
-
90
-
-
85041118637
-
The immunology of hepatocellular carcinoma
-
Ringelhan, M.; Pfister, D.; O’Connor, T.; Pikarsky, E.; Heikenwalder, M. The immunology of hepatocellular carcinoma. Nat. Immunol. 2018, 19, 222–232. [CrossRef] [PubMed]
-
(2018)
Nat. Immunol.
, vol.19
, pp. 222-232
-
-
Ringelhan, M.1
Pfister, D.2
O’Connor, T.3
Pikarsky, E.4
Heikenwalder, M.5
-
91
-
-
84922394053
-
Regulated cell death and inflammation: An auto-amplification loop causes organ failure
-
Linkermann, A.; Stockwell, B.R.; Krautwald, S.; Anders, H.J. Regulated cell death and inflammation: An auto-amplification loop causes organ failure. Nat. Rev. Immunol. 2014, 14, 759–767. [CrossRef] [PubMed]
-
(2014)
Nat. Rev. Immunol.
, vol.14
, pp. 759-767
-
-
Linkermann, A.1
Stockwell, B.R.2
Krautwald, S.3
Anders, H.J.4
-
92
-
-
84936891896
-
Inflammasomes: Mechanism of action, role in disease, and therapeutics
-
Guo, H.; Callaway, J.B.; Ting, J.P.Y. Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nat. Med. 2015, 21, 677. [CrossRef] [PubMed]
-
(2015)
Nat. Med.
, vol.21
, pp. 677
-
-
Guo, H.1
Callaway, J.B.2
Ting, J.P.Y.3
-
93
-
-
74549206702
-
How the noninflammasome NLRs function in the innate immune system
-
Ting, J.P.; Duncan, J.A.; Lei, Y. How the noninflammasome NLRs function in the innate immune system. Science 2010, 327, 286–290. [CrossRef] [PubMed]
-
(2010)
Science
, vol.327
, pp. 286-290
-
-
Ting, J.P.1
Duncan, J.A.2
Lei, Y.3
-
94
-
-
84858761335
-
Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1
-
Gross, O.; Yazdi, A.S.; Thomas, C.J.; Masin, M.; Heinz, L.X.; Guarda, G.; Quadroni, M.; Drexler, S.K.; Tschopp, J. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012, 36, 388–400. [CrossRef] [PubMed]
-
(2012)
Immunity
, vol.36
, pp. 388-400
-
-
Gross, O.1
Yazdi, A.S.2
Thomas, C.J.3
Masin, M.4
Heinz, L.X.5
Guarda, G.6
Quadroni, M.7
Drexler, S.K.8
Tschopp, J.9
-
95
-
-
70350569295
-
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors
-
Ghiringhelli, F.; Apetoh, L.; Tesniere, A.; Aymeric, L.; Ma, Y.; Ortiz, C.; Vermaelen, K.; Panaretakis, T.; Mignot, G.; Ullrich, E.; et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15, 1170–1178. [CrossRef] [PubMed]
-
(2009)
Nat. Med.
, vol.15
, pp. 1170-1178
-
-
Ghiringhelli, F.1
Apetoh, L.2
Tesniere, A.3
Aymeric, L.4
Ma, Y.5
Ortiz, C.6
Vermaelen, K.7
Panaretakis, T.8
Mignot, G.9
Ullrich, E.10
-
96
-
-
69949105157
-
The NLRP3 inflammasome: A sensor of immune danger signals
-
Cassel, S.L.; Joly, S.; Sutterwala, F.S. The NLRP3 inflammasome: A sensor of immune danger signals. Semin. Immunol. 2009, 21, 194–198. [CrossRef] [PubMed]
-
(2009)
Semin. Immunol.
, vol.21
, pp. 194-198
-
-
Cassel, S.L.1
Joly, S.2
Sutterwala, F.S.3
-
97
-
-
84930788521
-
Beyond canonical inflammasomes: Emerging pathways in IL-1-mediated autoinflammatory disease
-
Lukens, J.R.; Kanneganti, T.D. Beyond canonical inflammasomes: Emerging pathways in IL-1-mediated autoinflammatory disease. Semin. Immunopathol. 2014, 36, 595–609. [CrossRef] [PubMed]
-
(2014)
Semin. Immunopathol.
, vol.36
, pp. 595-609
-
-
Lukens, J.R.1
Kanneganti, T.D.2
-
98
-
-
84906247578
-
Inflammasome activation has an important role in the development of spontaneous colitis
-
Zhang, J.; Fu, S.; Sun, S.; Li, Z.; Guo, B. Inflammasome activation has an important role in the development of spontaneous colitis. Mucosal Immunol. 2014, 7, 1139–1150. [CrossRef] [PubMed]
-
(2014)
Mucosal Immunol
, vol.7
, pp. 1139-1150
-
-
Zhang, J.1
Fu, S.2
Sun, S.3
Li, Z.4
Guo, B.5
-
99
-
-
84901310586
-
Mechanisms and functions of inflammasomes
-
Lamkanfi, M.; Dixit, V.M. Mechanisms and functions of inflammasomes. Cell 2014, 157, 1013–1022. [CrossRef] [PubMed]
-
(2014)
Cell
, vol.157
, pp. 1013-1022
-
-
Lamkanfi, M.1
Dixit, V.M.2
-
100
-
-
84858643750
-
Inflammasomes in carcinogenesis and anticancer immune responses
-
Zitvogel, L.; Kepp, O.; Galluzzi, L.; Kroemer, G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 2012, 13, 343–351. [CrossRef] [PubMed]
-
(2012)
Nat. Immunol.
, vol.13
, pp. 343-351
-
-
Zitvogel, L.1
Kepp, O.2
Galluzzi, L.3
Kroemer, G.4
-
101
-
-
79956300649
-
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
-
Kawai, T.; Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34, 637–650. [CrossRef] [PubMed]
-
(2011)
Immunity
, vol.34
, pp. 637-650
-
-
Kawai, T.1
Akira, S.2
-
102
-
-
84918564833
-
Toll-like receptor signaling pathways
-
Kawasaki, T.; Kawai, T. Toll-like receptor signaling pathways. Front. Immunol. 2014, 5, 461. [CrossRef] [PubMed]
-
(2014)
Front. Immunol.
, vol.5
, pp. 461
-
-
Kawasaki, T.1
Kawai, T.2
-
103
-
-
0036671894
-
The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta
-
Martinon, F.; Burns, K.; Tschopp, J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 2002, 10, 417–426. [CrossRef]
-
(2002)
Mol. Cell
, vol.10
, pp. 417-426
-
-
Martinon, F.1
Burns, K.2
Tschopp, J.3
-
104
-
-
66749174867
-
The inflammasomes: Guardians of the body
-
Martinon, F.; Mayor, A.; Tschopp, J. The inflammasomes: Guardians of the body. Ann. Rev. Immunol. 2009, 27, 229–265. [CrossRef] [PubMed]
-
(2009)
Ann. Rev. Immunol.
, vol.27
, pp. 229-265
-
-
Martinon, F.1
Mayor, A.2
Tschopp, J.3
-
105
-
-
39149116674
-
NLR, the nucleotide-binding domain leucine-rich repeat containing gene family
-
Ye, Z.; Ting, J.P. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr. Opin. Immunol. 2008, 20, 3–9. [CrossRef] [PubMed]
-
(2008)
Curr. Opin. Immunol.
, vol.20
, pp. 3-9
-
-
Ye, Z.1
Ting, J.P.2
-
106
-
-
79951578449
-
Inflammasomes: Current understanding and open questions
-
Bauernfeind, F.; Ablasser, A.; Bartok, E.; Kim, S.; Schmid-Burgk, J.; Cavlar, T.; Hornung, V. Inflammasomes: Current understanding and open questions. Cell. Mol. Life Sci. CMLS 2011, 68, 765–783. [CrossRef] [PubMed]
-
(2011)
Cell. Mol. Life Sci. CMLS
, vol.68
, pp. 765-783
-
-
Bauernfeind, F.1
Ablasser, A.2
Bartok, E.3
Kim, S.4
Schmid-Burgk, J.5
Cavlar, T.6
Hornung, V.7
-
107
-
-
67049158193
-
The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1
-
Cayrol, C.; Girard, J.P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc. Natl. Acad. Sci. USA 2009, 106, 9021–9026. [CrossRef] [PubMed]
-
(2009)
Proc. Natl. Acad. Sci. USA
, vol.106
, pp. 9021-9026
-
-
Cayrol, C.1
Girard, J.P.2
-
108
-
-
77950362382
-
The inflammasomes
-
Schroder, K.; Tschopp, J. The inflammasomes. Cell 2010, 140, 821–832. [CrossRef] [PubMed]
-
(2010)
Cell
, vol.140
, pp. 821-832
-
-
Schroder, K.1
Tschopp, J.2
-
109
-
-
79959573042
-
Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells
-
Csak, T.; Ganz, M.; Pespisa, J.; Kodys, K.; Dolganiuc, A.; Szabo, G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011, 54, 133–144. [CrossRef] [PubMed]
-
(2011)
Hepatology
, vol.54
, pp. 133-144
-
-
Csak, T.1
Ganz, M.2
Pespisa, J.3
Kodys, K.4
Dolganiuc, A.5
Szabo, G.6
-
110
-
-
84870062861
-
Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease
-
Boaru, S.G.; Borkham-Kamphorst, E.; Tihaa, L.; Haas, U.; Weiskirchen, R. Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease. J. Inflamm. 2012, 9, 49. [CrossRef] [PubMed]
-
(2012)
J. Inflamm.
, vol.9
, pp. 49
-
-
Boaru, S.G.1
Borkham-Kamphorst, E.2
Tihaa, L.3
Haas, U.4
Weiskirchen, R.5
-
111
-
-
78650859531
-
NF-κB and STAT3–key players in liver inflammation and cancer
-
He, G.; Karin, M. NF-κB and STAT3–key players in liver inflammation and cancer. Cell Res. 2011, 21, 159–168. [CrossRef] [PubMed]
-
(2011)
Cell Res
, vol.21
, pp. 159-168
-
-
He, G.1
Karin, M.2
-
112
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef] [PubMed]
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
113
-
-
79751492851
-
NF-κB in the liver—Linking injury, fibrosis and hepatocellular carcinoma
-
Luedde, T.; Schwabe, R.F. NF-κB in the liver—Linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 108–118. [CrossRef] [PubMed]
-
(2011)
Nat. Rev. Gastroenterol. Hepatol.
, vol.8
, pp. 108-118
-
-
Luedde, T.1
Schwabe, R.F.2
-
114
-
-
0034046605
-
STAT family of transcription factors in cytokine-mediated biological responses
-
Takeda, K.; Akira, S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev. 2000, 11, 199–207. [CrossRef]
-
(2000)
Cytokine Growth Factor Rev
, vol.11
, pp. 199-207
-
-
Takeda, K.1
Akira, S.2
-
115
-
-
0034658541
-
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
-
Hirano, T.; Ishihara, K.; Hibi, M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000, 19, 2548–2556. [CrossRef] [PubMed]
-
(2000)
Oncogene
, vol.19
, pp. 2548-2556
-
-
Hirano, T.1
Ishihara, K.2
Hibi, M.3
-
116
-
-
85026219642
-
New insights into the role of autophagy in tumor immune microenvironment
-
Li, C.J.; Liao, W.T.; Wu, M.Y.; Chu, P.Y. New insights into the role of autophagy in tumor immune microenvironment. Int. J. Mol. Sci. 2017, 18, 1566. [CrossRef] [PubMed]
-
(2017)
Int. J. Mol. Sci.
, vol.18
, pp. 1566
-
-
Li, C.J.1
Liao, W.T.2
Wu, M.Y.3
Chu, P.Y.4
-
117
-
-
0036379718
-
Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma
-
Matsui, M.; Machida, S.; Itani-Yohda, T.; Akatsuka, T. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma. J. Gastroenterol. Hepatol. 2002, 17, 897–907. [CrossRef] [PubMed]
-
(2002)
J. Gastroenterol. Hepatol.
, vol.17
, pp. 897-907
-
-
Matsui, M.1
Machida, S.2
Itani-Yohda, T.3
Akatsuka, T.4
-
118
-
-
16844378685
-
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma
-
Ormandy, L.A.; Hillemann, T.; Wedemeyer, H.; Manns, M.P.; Greten, T.F.; Korangy, F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005, 65, 2457–2464. [CrossRef] [PubMed]
-
(2005)
Cancer Res
, vol.65
, pp. 2457-2464
-
-
Ormandy, L.A.1
Hillemann, T.2
Wedemeyer, H.3
Manns, M.P.4
Greten, T.F.5
Korangy, F.6
-
119
-
-
16244393380
-
Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells
-
Unitt, E.; Rushbrook, S.M.; Marshall, A.; Davies, S.; Gibbs, P.; Morris, L.S.; Coleman, N.; Alexander, G.J. Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells. Hepatology 2005, 41, 722–730. [CrossRef] [PubMed]
-
(2005)
Hepatology
, vol.41
, pp. 722-730
-
-
Unitt, E.1
Rushbrook, S.M.2
Marshall, A.3
Davies, S.4
Gibbs, P.5
Morris, L.S.6
Coleman, N.7
Alexander, G.J.8
-
120
-
-
84857743064
-
Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma
-
Cariani, E.; Pilli, M.; Zerbini, A.; Rota, C.; Olivani, A.; Pelosi, G.; Schianchi, C.; Soliani, P.; Campanini, N.; Silini, E.M.; et al. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS ONE 2012, 7, e32493. [CrossRef] [PubMed]
-
(2012)
Plos ONE
, vol.7
-
-
Cariani, E.1
Pilli, M.2
Zerbini, A.3
Rota, C.4
Olivani, A.5
Pelosi, G.6
Schianchi, C.7
Soliani, P.8
Campanini, N.9
Silini, E.M.10
-
121
-
-
46049098560
-
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells
-
Hoechst, B.; Ormandy, L.A.; Ballmaier, M.; Lehner, F.; Kruger, C.; Manns, M.P.; Greten, T.F.; Korangy, F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008, 135, 234–243. [CrossRef] [PubMed]
-
(2008)
Gastroenterology
, vol.135
, pp. 234-243
-
-
Hoechst, B.1
Ormandy, L.A.2
Ballmaier, M.3
Lehner, F.4
Kruger, C.5
Manns, M.P.6
Greten, T.F.7
Korangy, F.8
-
122
-
-
45749137283
-
High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma
-
Zhu, X.D.; Zhang, J.B.; Zhuang, P.Y.; Zhu, H.G.; Zhang, W.; Xiong, Y.Q.; Wu, W.Z.; Wang, L.; Tang, Z.Y.; Sun, H.C. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008, 26, 2707–2716. [CrossRef] [PubMed]
-
(2008)
J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol
, vol.26
, pp. 2707-2716
-
-
Zhu, X.D.1
Zhang, J.B.2
Zhuang, P.Y.3
Zhu, H.G.4
Zhang, W.5
Xiong, Y.Q.6
Wu, W.Z.7
Wang, L.8
Tang, Z.Y.9
Sun, H.C.10
-
123
-
-
84922980334
-
Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma
-
Yeung, O.W.; Lo, C.M.; Ling, C.C.; Qi, X.; Geng, W.; Li, C.X.; Ng, K.T.; Forbes, S.J.; Guan, X.Y.; Poon, R.T.; et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J. Hepatol. 2015, 62, 607–616. [CrossRef] [PubMed]
-
(2015)
J. Hepatol.
, vol.62
, pp. 607-616
-
-
Yeung, O.W.1
Lo, C.M.2
Ling, C.C.3
Qi, X.4
Geng, W.5
Li, C.X.6
Ng, K.T.7
Forbes, S.J.8
Guan, X.Y.9
Poon, R.T.10
-
124
-
-
59049106749
-
High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection
-
Ding, T.; Xu, J.; Wang, F.; Shi, M.; Zhang, Y.; Li, S.P.; Zheng, L. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum. Pathol. 2009, 40, 381–389. [CrossRef] [PubMed]
-
(2009)
Hum. Pathol.
, vol.40
, pp. 381-389
-
-
Ding, T.1
Xu, J.2
Wang, F.3
Shi, M.4
Zhang, Y.5
Li, S.P.6
Zheng, L.7
-
125
-
-
76949094210
-
Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease
-
Behboudi, S.; Alisa, A.; Boswell, S.; Anastassiou, J.; Pathan, A.A.; Williams, R. Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease. Br. J. Cancer 2010, 102, 748–753. [CrossRef] [PubMed]
-
(2010)
Br. J. Cancer
, vol.102
, pp. 748-753
-
-
Behboudi, S.1
Alisa, A.2
Boswell, S.3
Anastassiou, J.4
Pathan, A.A.5
Williams, R.6
-
126
-
-
85030100079
-
New insights into the role of inflammation in the pathogenesis of atherosclerosis
-
Wu, M.-Y.; Li, C.-J.; Hou, M.-F.; Chu, P.-Y. New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int. J. Mol. Sci. 2017, 18, 2034. [CrossRef] [PubMed]
-
(2017)
Int. J. Mol. Sci.
, vol.18
, pp. 2034
-
-
Wu, M.-Y.1
Li, C.-J.2
Hou, M.-F.3
Chu, P.-Y.4
-
127
-
-
85116953324
-
Role of nonresolving inflammation in hepatocellular carcinoma development and progression
-
Yu, L.-X.; Ling, Y.; Wang, H.-Y. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis. Oncol. 2018, 2, 6. [CrossRef] [PubMed]
-
(2018)
NPJ Precis. Oncol.
, vol.2
, pp. 6
-
-
Yu, L.-X.1
Ling, Y.2
Wang, H.-Y.3
-
128
-
-
33747029250
-
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment
-
Budhu, A.; Forgues, M.; Ye, Q.H.; Jia, H.L.; He, P.; Zanetti, K.A.; Kammula, U.S.; Chen, Y.; Qin, L.X.; Tang, Z.Y.; et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10, 99–111. [CrossRef] [PubMed]
-
(2006)
Cancer Cell
, vol.10
, pp. 99-111
-
-
Budhu, A.1
Forgues, M.2
Ye, Q.H.3
Jia, H.L.4
He, P.5
Zanetti, K.A.6
Kammula, U.S.7
Chen, Y.8
Qin, L.X.9
Tang, Z.Y.10
-
129
-
-
0346895107
-
Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma
-
Hattori, E.; Okumoto, K.; Adachi, T.; Takeda, T.; Ito, J.; Sugahara, K.; Watanabe, H.; Saito, K.; Saito, T.; Togashi, H.; et al. Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatol. Res. Off. J. Jpn Soc. Hepatol. 2003, 27, 309–314. [CrossRef]
-
(2003)
Hepatol. Res. Off. J. Jpn Soc. Hepatol.
, vol.27
, pp. 309-314
-
-
Hattori, E.1
Okumoto, K.2
Adachi, T.3
Takeda, T.4
Ito, J.5
Sugahara, K.6
Watanabe, H.7
Saito, K.8
Saito, T.9
Togashi, H.10
-
130
-
-
84864215495
-
In vitro angiogenesis assay for the study of cell-encapsulation therapy
-
Kim, C.; Chung, S.; Yuchun, L.; Kim, M.C.; Chan, J.K.; Asada, H.H.; Kamm, R.D. In vitro angiogenesis assay for the study of cell-encapsulation therapy. Lab Chip 2012, 12, 2942–2950. [CrossRef] [PubMed]
-
(2012)
Lab Chip
, vol.12
, pp. 2942-2950
-
-
Kim, C.1
Chung, S.2
Yuchun, L.3
Kim, M.C.4
Chan, J.K.5
Asada, H.H.6
Kamm, R.D.7
-
131
-
-
84942551966
-
Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma
-
Won, C.; Kim, B.H.; Yi, E.H.; Choi, K.J.; Kim, E.K.; Jeong, J.M.; Lee, J.H.; Jang, J.J.; Yoon, J.H.; Jeong, W.I.; et al. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology 2015, 62, 1160–1173. [CrossRef] [PubMed]
-
(2015)
Hepatology
, vol.62
, pp. 1160-1173
-
-
Won, C.1
Kim, B.H.2
Yi, E.H.3
Choi, K.J.4
Kim, E.K.5
Jeong, J.M.6
Lee, J.H.7
Jang, J.J.8
Yoon, J.H.9
Jeong, W.I.10
-
132
-
-
84938745385
-
Programmed probiotics light up liver cancer in urine
-
Ray, K. Diagnosis: Programmed probiotics light up liver cancer in urine. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 429. [CrossRef] [PubMed]
-
(2015)
Nat. Rev. Gastroenterol. Hepatol.
, vol.12
, pp. 429
-
-
Ray, K.D.1
-
133
-
-
84859812538
-
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4
-
Dapito, D.H.; Mencin, A.; Gwak, G.Y.; Pradere, J.P.; Jang, M.K.; Mederacke, I.; Caviglia, J.M.; Khiabanian, H.; Adeyemi, A.; Bataller, R.; et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21, 504–516. [CrossRef] [PubMed]
-
(2012)
Cancer Cell
, vol.21
, pp. 504-516
-
-
Dapito, D.H.1
Mencin, A.2
Gwak, G.Y.3
Pradere, J.P.4
Jang, M.K.5
Mederacke, I.6
Caviglia, J.M.7
Khiabanian, H.8
Adeyemi, A.9
Bataller, R.10
-
134
-
-
84979090945
-
Nutrition status and small intestinal bacterial overgrowth in patients with virus-related cirrhosis
-
PubMed
-
Yao, J.; Chang, L.; Yuan, L.; Duan, Z. Nutrition status and small intestinal bacterial overgrowth in patients with virus-related cirrhosis. Asia Pac. J. Clin. Nutr. 2016, 25, 283–291. [PubMed]
-
(2016)
Asia Pac. J. Clin. Nutr.
, vol.25
, pp. 283-291
-
-
Yao, J.1
Chang, L.2
Yuan, L.3
Duan, Z.4
-
135
-
-
84959440187
-
TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells
-
Lin, A.; Wang, G.; Zhao, H.; Zhang, Y.; Han, Q.; Zhang, C.; Tian, Z.; Zhang, J. TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells. Oncoimmunology 2016, 5, e1074376. [CrossRef] [PubMed]
-
(2016)
Oncoimmunology
, vol.5
-
-
Lin, A.1
Wang, G.2
Zhao, H.3
Zhang, Y.4
Han, Q.5
Zhang, C.6
Tian, Z.7
Zhang, J.8
-
136
-
-
85046692457
-
Efficacy and Safety of neoadjuvant treatment with bevacizumab, liposomal doxorubicin, cyclophosphamide and paclitaxel combination in locally/regionally advanced, HER2-negative, Grade III at premenopausal status breast cancer: A Phase II Study
-
Tampaki, E.C.; Tampakis, A.; Alifieris, C.E.; Krikelis, D.; Pazaiti, A.; Kontos, M.; Trafalis, D.T. Efficacy and Safety of neoadjuvant treatment with bevacizumab, liposomal doxorubicin, cyclophosphamide and paclitaxel combination in locally/regionally advanced, HER2-negative, Grade III at premenopausal status breast cancer: A Phase II Study. Clin. Drug Investig. 2018. [CrossRef] [PubMed]
-
(2018)
Clin. Drug Investig.
-
-
Tampaki, E.C.1
Tampakis, A.2
Alifieris, C.E.3
Krikelis, D.4
Pazaiti, A.5
Kontos, M.6
Trafalis, D.T.7
-
137
-
-
84974661147
-
Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen
-
Gonzalez-Vacarezza, N.; Alonso, I.; Arroyo, G.; Martinez, J.; De Andres, F.; LLerena, A.; Estevez-Carrizo, F. Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen. Drug Metab. Pers. Ther. 2016, 31, 83–90. [CrossRef] [PubMed]
-
(2016)
Drug Metab. Pers. Ther.
, vol.31
, pp. 83-90
-
-
Gonzalez-Vacarezza, N.1
Alonso, I.2
Arroyo, G.3
Martinez, J.4
de Andres, F.5
Llerena, A.6
Estevez-Carrizo, F.7
-
138
-
-
84948844664
-
Hepatocellular carcinoma: A Phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo
-
Pinter, M.; Ulbrich, G.; Sieghart, W.; Kolblinger, C.; Reiberger, T.; Li, S.; Ferlitsch, A.; Muller, C.; Lammer, J.; Peck-Radosavljevic, M. Hepatocellular carcinoma: A Phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo. Radiology 2015, 277, 903–912. [CrossRef] [PubMed]
-
(2015)
Radiology
, vol.277
, pp. 903-912
-
-
Pinter, M.1
Ulbrich, G.2
Sieghart, W.3
Kolblinger, C.4
Reiberger, T.5
Li, S.6
Ferlitsch, A.7
Muller, C.8
Lammer, J.9
Peck-Radosavljevic, M.10
-
139
-
-
84961566836
-
Efficacy, safety, and potential biomarkers of sunitinib and transarterial chemoembolization (TACE) combination in advanced hepatocellular carcinoma (HCC): Phase II trial
-
Pokuri, V.K.; Tomaszewski, G.M.; Ait-Oudhia, S.; Groman, A.; Khushalani, N.I.; Lugade, A.A.; Thanavala, Y.; Ashton, E.A.; Grande, C.; Fetterly, G.J.; et al. Efficacy, safety, and potential biomarkers of sunitinib and transarterial chemoembolization (TACE) combination in advanced hepatocellular carcinoma (HCC): Phase II trial. Am. J. Clin. Oncol. 2018, 41, 332–338. [CrossRef] [PubMed]
-
(2018)
Am. J. Clin. Oncol
, vol.41
, pp. 332-338
-
-
Pokuri, V.K.1
Tomaszewski, G.M.2
Ait-Oudhia, S.3
Groman, A.4
Khushalani, N.I.5
Lugade, A.A.6
Thanavala, Y.7
Ashton, E.A.8
Grande, C.9
Fetterly, G.J.10
-
140
-
-
84891915708
-
Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial
-
Cheng, A.L.; Kang, Y.K.; Lin, D.Y.; Park, J.W.; Kudo, M.; Qin, S.; Chung, H.C.; Song, X.; Xu, J.; Poggi, G.; et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J. Clin. Oncol. 2013, 31, 4067–4075. [CrossRef] [PubMed]
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 4067-4075
-
-
Cheng, A.L.1
Kang, Y.K.2
Lin, D.Y.3
Park, J.W.4
Kudo, M.5
Qin, S.6
Chung, H.C.7
Song, X.8
Xu, J.9
Poggi, G.10
-
141
-
-
78249288161
-
Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: Implication for antiangiogenic approach to hepatocellular carcinoma
-
Yau, T.; Chan, P.; Pang, R.; Ng, K.; Fan, S.T.; Poon, R.T. Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: Implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 2010, 116, 5022–5029. [CrossRef] [PubMed]
-
(2010)
Cancer
, vol.116
, pp. 5022-5029
-
-
Yau, T.1
Chan, P.2
Pang, R.3
Ng, K.4
Fan, S.T.5
Poon, R.T.6
-
142
-
-
85041472350
-
Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study
-
Yu, W.C.; Zhang, K.Z.; Chen, S.G.; Liu, W.F. Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study. Medicine 2018, 97, e9704. [CrossRef] [PubMed]
-
(2018)
Medicine
, vol.97
-
-
Yu, W.C.1
Zhang, K.Z.2
Chen, S.G.3
Liu, W.F.4
-
143
-
-
85036543651
-
Apatinib is effective for treatment of advanced hepatocellular carcinoma
-
Kong, Y.; Sun, L.; Hou, Z.; Zhang, Y.; Chen, P.; Cui, Y.; Zhu, X.; Song, T.; Li, Q.; Li, H.; et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget 2017, 8, 105596–105605. [CrossRef] [PubMed]
-
(2017)
Oncotarget
, vol.8
, pp. 105596-105605
-
-
Kong, Y.1
Sun, L.2
Hou, Z.3
Zhang, Y.4
Chen, P.5
Cui, Y.6
Zhu, X.7
Song, T.8
Li, Q.9
Li, H.10
-
144
-
-
84920993186
-
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial
-
Cainap, C.; Qin, S.; Huang, W.T.; Chung, I.J.; Pan, H.; Cheng, Y.; Kudo, M.; Kang, Y.K.; Chen, P.J.; Toh, H.C.; et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J. Clin. Oncol. 2015, 33, 172–179. [CrossRef] [PubMed]
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 172-179
-
-
Cainap, C.1
Qin, S.2
Huang, W.T.3
Chung, I.J.4
Pan, H.5
Cheng, Y.6
Kudo, M.7
Kang, Y.K.8
Chen, P.J.9
Toh, H.C.10
-
145
-
-
84888001200
-
Exposure-response (Safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma
-
Chiu, Y.L.; Carlson, D.M.; Pradhan, R.S.; Ricker, J.L. Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma. Clin. Ther. 2013, 35, 1770–1777. [CrossRef] [PubMed]
-
(2013)
Clin. Ther.
, vol.35
, pp. 1770-1777
-
-
Chiu, Y.L.1
Carlson, D.M.2
Pradhan, R.S.3
Ricker, J.L.4
-
146
-
-
84954621530
-
TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet’s syndrome refractory to the conventional treatment modalities: A case series and review of the literature
-
Hatemi, I.; Hatemi, G.; Pamuk, O.N.; Erzin, Y.; Celik, A.F. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet’s syndrome refractory to the conventional treatment modalities: A case series and review of the literature. Clin. Exp. Rheumatol. 2015, 33 (Suppl. 94), S129–S137. [PubMed]
-
(2015)
Clin. Exp. Rheumatol
, vol.33
, Issue.94
, pp. S129-S137
-
-
Hatemi, I.1
Hatemi, G.2
Pamuk, O.N.3
Erzin, Y.4
Celik, A.F.5
-
147
-
-
77949716939
-
Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways
-
Segarra, M.; Lozano, E.; Corbera-Bellalta, M.; Vilardell, C.; Cibeira, M.T.; Esparza, J.; Izco, N.; Blade, J.; Cid, M.C. Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica 2010, 95, 456–463. [CrossRef] [PubMed]
-
(2010)
Haematologica
, vol.95
, pp. 456-463
-
-
Segarra, M.1
Lozano, E.2
Corbera-Bellalta, M.3
Vilardell, C.4
Cibeira, M.T.5
Esparza, J.6
Izco, N.7
Blade, J.8
Cid, M.C.9
-
148
-
-
85021845807
-
Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: A systematic review and meta-analysis
-
Cao, D.D.; Xu, H.L.; Liu, L.; Zheng, Y.F.; Gao, S.F.; Xu, X.M.; Ge, W. Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: A systematic review and meta-analysis. Oncotarget 2017, 8, 44976–44993. [CrossRef] [PubMed]
-
(2017)
Oncotarget
, vol.8
, pp. 44976-44993
-
-
Cao, D.D.1
Xu, H.L.2
Liu, L.3
Zheng, Y.F.4
Gao, S.F.5
Xu, X.M.6
Ge, W.7
-
149
-
-
84856051012
-
Sorafenib: Complexities of Raf-dependent and Raf-independent signaling are now unveiled
-
Matsuda, Y.; Fukumoto, M. Sorafenib: Complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med. Mol. Morphol. 2011, 44, 183–189. [CrossRef] [PubMed]
-
(2011)
Med. Mol. Morphol.
, vol.44
, pp. 183-189
-
-
Matsuda, Y.1
Fukumoto, M.2
-
150
-
-
84873949249
-
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update
-
Gauthier, A.; Ho, M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol. Res. 2013, 43, 147–154. [CrossRef] [PubMed]
-
(2013)
Hepatol. Res.
, vol.43
, pp. 147-154
-
-
Gauthier, A.1
Ho, M.2
-
151
-
-
57349122313
-
Sorafenib in advanced hepatocellular carcinoma
-
Palmer, D.H. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378–390.
-
(2008)
N. Engl. J. Med.
, vol.359
, pp. 378-390
-
-
Palmer, D.H.1
-
152
-
-
85042088471
-
Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: A secondary analysis of a phase III study
-
Abdel-Rahman, O. Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: A secondary analysis of a phase III study. J. Cancer Res. Clin. Oncol. 2018, 144, 901–908. [CrossRef] [PubMed]
-
(2018)
J. Cancer Res. Clin. Oncol.
, vol.144
, pp. 901-908
-
-
Abdel-Rahman, O.1
-
153
-
-
57349087153
-
Pivotal role of mTOR signaling in hepatocellular carcinoma
-
Villanueva, A.; Chiang, D.Y.; Newell, P.; Peix, J.; Thung, S.; Alsinet, C.; Tovar, V.; Roayaie, S.; Minguez, B.; Sole, M.; et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008, 135, 1972–1983. [CrossRef] [PubMed]
-
(2008)
Gastroenterology
, vol.135
, pp. 1972-1983
-
-
Villanueva, A.1
Chiang, D.Y.2
Newell, P.3
Peix, J.4
Thung, S.5
Alsinet, C.6
Tovar, V.7
Roayaie, S.8
Minguez, B.9
Sole, M.10
-
154
-
-
84892979090
-
Recent developments of small molecule PI3K/mTOR dual inhibitors
-
Liu, Y.N.; Wan, R.Z.; Liu, Z.P. Recent developments of small molecule PI3K/mTOR dual inhibitors. Mini Rev. Med. Chem. 2013, 13, 2047–2059. [CrossRef] [PubMed]
-
(2013)
Mini Rev. Med. Chem.
, vol.13
, pp. 2047-2059
-
-
Liu, Y.N.1
Wan, R.Z.2
Liu, Z.P.3
-
155
-
-
63549114458
-
Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma
-
Wang, Z.; Zhou, J.; Fan, J.; Tan, C.J.; Qiu, S.J.; Yu, Y.; Huang, X.W.; Tang, Z.Y. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2009, 135, 715–722. [CrossRef] [PubMed]
-
(2009)
J. Cancer Res. Clin. Oncol.
, vol.135
, pp. 715-722
-
-
Wang, Z.1
Zhou, J.2
Fan, J.3
Tan, C.J.4
Qiu, S.J.5
Yu, Y.6
Huang, X.W.7
Tang, Z.Y.8
-
156
-
-
84952324338
-
Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label Phase 3 trial
-
Geissler, E.K.; Schnitzbauer, A.A.; Zulke, C.; Lamby, P.E.; Proneth, A.; Duvoux, C.; Burra, P.; Jauch, K.W.; Rentsch, M.; Ganten, T.M.; et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label Phase 3 trial. Transplantation 2016, 100, 116–125. [CrossRef] [PubMed]
-
(2016)
Transplantation
, vol.100
, pp. 116-125
-
-
Geissler, E.K.1
Schnitzbauer, A.A.2
Zulke, C.3
Lamby, P.E.4
Proneth, A.5
Duvoux, C.6
Burra, P.7
Jauch, K.W.8
Rentsch, M.9
Ganten, T.M.10
-
157
-
-
84964786369
-
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): A randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
-
Koeberle, D.; Dufour, J.F.; Demeter, G.; Li, Q.; Ribi, K.; Samaras, P.; Saletti, P.; Roth, A.D.; Horber, D.; Buehlmann, M.; et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): A randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann. Oncol. 2016, 27, 856–861. [CrossRef] [PubMed]
-
(2016)
Ann. Oncol.
, vol.27
, pp. 856-861
-
-
Koeberle, D.1
Dufour, J.F.2
Demeter, G.3
Li, Q.4
Ribi, K.5
Samaras, P.6
Saletti, P.7
Roth, A.D.8
Horber, D.9
Buehlmann, M.10
-
158
-
-
0035395236
-
Ng, I.O. β-Catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance
-
Wong, C.M.; Fan, S.T.; Ng, I.O. β-Catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance. Cancer 2001, 92, 136–145. [CrossRef]
-
(2001)
Cancer
, vol.92
, pp. 136-145
-
-
Wong, C.M.1
Fan, S.T.2
-
159
-
-
84991063920
-
Direct targeting of beta-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/beta-catenin signaling
-
Hwang, S.Y.; Deng, X.; Byun, S.; Lee, C.; Lee, S.J.; Suh, H.; Zhang, J.; Kang, Q.; Zhang, T.; Westover, K.D.; et al. Direct targeting of beta-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/beta-catenin signaling. Cell Rep. 2016, 16, 28–36. [CrossRef] [PubMed]
-
(2016)
Cell Rep
, vol.16
, pp. 28-36
-
-
Hwang, S.Y.1
Deng, X.2
Byun, S.3
Lee, C.4
Lee, S.J.5
Suh, H.6
Zhang, J.7
Kang, Q.8
Zhang, T.9
Westover, K.D.10
-
160
-
-
26444584958
-
Nuclear factor-kappaB and liver carcinogenesis
-
Arsura, M.; Cavin, L.G. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett. 2005, 229, 157–169. [CrossRef] [PubMed]
-
(2005)
Cancer Lett
, vol.229
, pp. 157-169
-
-
Arsura, M.1
Cavin, L.G.2
-
161
-
-
84873282409
-
Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib
-
Wahl, K.; Siegemund, M.; Lehner, F.; Vondran, F.; Nussler, A.; Langer, F.; Krech, T.; Kontermann, R.; Manns, M.P.; Schulze-Osthoff, K.; et al. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology 2013, 57, 625–636. [CrossRef] [PubMed]
-
(2013)
Hepatology
, vol.57
, pp. 625-636
-
-
Wahl, K.1
Siegemund, M.2
Lehner, F.3
Vondran, F.4
Nussler, A.5
Langer, F.6
Krech, T.7
Kontermann, R.8
Manns, M.P.9
Schulze-Osthoff, K.10
-
162
-
-
84856554756
-
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma
-
Kim, G.P.; Mahoney, M.R.; Szydlo, D.; Mok, T.S.; Marshke, R.; Holen, K.; Picus, J.; Boyer, M.; Pitot, H.C.; Rubin, J.; et al. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investig. New Drugs 2012, 30, 387–394. [CrossRef] [PubMed]
-
(2012)
Investig. New Drugs
, vol.30
, pp. 387-394
-
-
Kim, G.P.1
Mahoney, M.R.2
Szydlo, D.3
Mok, T.S.4
Marshke, R.5
Holen, K.6
Picus, J.7
Boyer, M.8
Pitot, H.C.9
Rubin, J.10
-
163
-
-
84873736254
-
Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities
-
Pardee, A.D.; Butterfield, L.H. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology 2012, 1, 48–55. [CrossRef] [PubMed]
-
(2012)
Oncoimmunology
, vol.1
, pp. 48-55
-
-
Pardee, A.D.1
Butterfield, L.H.2
-
164
-
-
84879141840
-
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
-
Sangro, B.; Gomez-Martin, C.; de la Mata, M.; Inarrairaegui, M.; Garralda, E.; Barrera, P.; Riezu-Boj, J.I.; Larrea, E.; Alfaro, C.; Sarobe, P.; et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 2013, 59, 81–88. [CrossRef] [PubMed]
-
(2013)
J. Hepatol.
, vol.59
, pp. 81-88
-
-
Sangro, B.1
Gomez-Martin, C.2
de la Mata, M.3
Inarrairaegui, M.4
Garralda, E.5
Barrera, P.6
Riezu-Boj, J.I.7
Larrea, E.8
Alfaro, C.9
Sarobe, P.10
-
165
-
-
77951240589
-
Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome
-
Juliana, C.; Fernandes-Alnemri, T.; Wu, J.; Datta, P.; Solorzano, L.; Yu, J.W.; Meng, R.; Quong, A.A.; Latz, E.; Scott, C.P.; et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J. Biol. Chem. 2010, 285, 9792–9802. [CrossRef] [PubMed]
-
(2010)
J. Biol. Chem.
, vol.285
, pp. 9792-9802
-
-
Juliana, C.1
Fernandes-Alnemri, T.2
Wu, J.3
Datta, P.4
Solorzano, L.5
Yu, J.W.6
Meng, R.7
Quong, A.A.8
Latz, E.9
Scott, C.P.10
-
166
-
-
84914132421
-
Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation
-
Honda, H.; Nagai, Y.; Matsunaga, T.; Okamoto, N.; Watanabe, Y.; Tsuneyama, K.; Hayashi, H.; Fujii, I.; Ikutani, M.; Hirai, Y.; et al. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J. Leukoc. Biol. 2014, 96, 1087–1100. [CrossRef] [PubMed]
-
(2014)
J. Leukoc. Biol.
, vol.96
, pp. 1087-1100
-
-
Honda, H.1
Nagai, Y.2
Matsunaga, T.3
Okamoto, N.4
Watanabe, Y.5
Tsuneyama, K.6
Hayashi, H.7
Fujii, I.8
Ikutani, M.9
Hirai, Y.10
-
167
-
-
85006324215
-
Spirodalesol, an NLRP3 Inflammasome Activation Inhibitor
-
Zhang, A.H.; Liu, W.; Jiang, N.; Xu, Q.; Tan, R.X. Spirodalesol, an NLRP3 Inflammasome Activation Inhibitor. Org. Lett. 2016, 18, 6496–6499. [CrossRef] [PubMed]
-
(2016)
Org. Lett.
, vol.18
, pp. 6496-6499
-
-
Zhang, A.H.1
Liu, W.2
Jiang, N.3
Xu, Q.4
Tan, R.X.5
-
168
-
-
85006056586
-
Liver X receptors agonists suppress NLRP3 inflammasome activation
-
Yu, S.X.; Chen, W.; Hu, X.Z.; Feng, S.Y.; Li, K.Y.; Qi, S.; Lei, Q.Q.; Hu, G.Q.; Li, N.; Zhou, F.H.; et al. Liver X receptors agonists suppress NLRP3 inflammasome activation. Cytokine 2017, 91, 30–37. [CrossRef] [PubMed]
-
(2017)
Cytokine
, vol.91
, pp. 30-37
-
-
Yu, S.X.1
Chen, W.2
Hu, X.Z.3
Feng, S.Y.4
Li, K.Y.5
Qi, S.6
Lei, Q.Q.7
Hu, G.Q.8
Li, N.9
Zhou, F.H.10
-
169
-
-
84963795296
-
A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet
-
Yang, G.; Lee, H.E.; Lee, J.Y. A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet. Sci. Rep. 2016, 6, 24399. [CrossRef] [PubMed]
-
(2016)
Sci. Rep.
, vol.6
-
-
Yang, G.1
Lee, H.E.2
Lee, J.Y.3
-
170
-
-
84924356420
-
The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
-
Youm, Y.H.; Nguyen, K.Y.; Grant, R.W.; Goldberg, E.L.; Bodogai, M.; Kim, D.; D’Agostino, D.; Planavsky, N.; Lupfer, C.; Kanneganti, T.D.; et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 2015, 21, 263–269. [CrossRef] [PubMed]
-
(2015)
Nat. Med.
, vol.21
, pp. 263-269
-
-
Youm, Y.H.1
Nguyen, K.Y.2
Grant, R.W.3
Goldberg, E.L.4
Bodogai, M.5
Kim, D.6
D’Agostino, D.7
Planavsky, N.8
Lupfer, C.9
Kanneganti, T.D.10
-
171
-
-
84924415042
-
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
-
Coll, R.C.; Robertson, A.A.; Chae, J.J.; Higgins, S.C.; Munoz-Planillo, R.; Inserra, M.C.; Vetter, I.; Dungan, L.S.; Monks, B.G.; Stutz, A.; et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 2015, 21, 248–255. [CrossRef] [PubMed]
-
(2015)
Nat. Med.
, vol.21
, pp. 248-255
-
-
Coll, R.C.1
Robertson, A.A.2
Chae, J.J.3
Higgins, S.C.4
Munoz-Planillo, R.5
Inserra, M.C.6
Vetter, I.7
Dungan, L.S.8
Monks, B.G.9
Stutz, A.10
-
172
-
-
77955475968
-
NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses
-
Gris, D.; Ye, Z.; Iocca, H.A.; Wen, H.; Craven, R.R.; Gris, P.; Huang, M.; Schneider, M.; Miller, S.D.; Ting, J.P. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 2010, 185, 974–981. [CrossRef] [PubMed]
-
(2010)
J. Immunol.
, vol.185
, pp. 974-981
-
-
Gris, D.1
Ye, Z.2
Iocca, H.A.3
Wen, H.4
Craven, R.R.5
Gris, P.6
Huang, M.7
Schneider, M.8
Miller, S.D.9
Ting, J.P.10
-
173
-
-
84862988248
-
NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis
-
Inoue, M.; Williams, K.L.; Gunn, M.D.; Shinohara, M.L. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2012, 109, 10480–10485. [CrossRef] [PubMed]
-
(2012)
Proc. Natl. Acad. Sci. USA
, vol.109
, pp. 10480-10485
-
-
Inoue, M.1
Williams, K.L.2
Gunn, M.D.3
Shinohara, M.L.4
-
174
-
-
84861473687
-
Interferon-beta therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome
-
Inoue, M.; Williams, K.L.; Oliver, T.; Vandenabeele, P.; Rajan, J.V.; Miao, E.A.; Shinohara, M.L. Interferon-beta therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci. Signal. 2012, 5, ra38. [CrossRef] [PubMed]
-
(2012)
Sci. Signal.
, vol.5
-
-
Inoue, M.1
Williams, K.L.2
Oliver, T.3
Vandenabeele, P.4
Rajan, J.V.5
Miao, E.A.6
Shinohara, M.L.7
-
175
-
-
17544383333
-
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
-
Llovet, J.M.; Sala, M.; Castells, L.; Suarez, Y.; Vilana, R.; Bianchi, L.; Ayuso, C.; Vargas, V.; Rodes, J.; Bruix, J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000, 31, 54–58. [CrossRef] [PubMed]
-
(2000)
Hepatology
, vol.31
, pp. 54-58
-
-
Llovet, J.M.1
Sala, M.2
Castells, L.3
Suarez, Y.4
Vilana, R.5
Bianchi, L.6
Ayuso, C.7
Vargas, V.8
Rodes, J.9
Bruix, J.10
-
176
-
-
0033854015
-
Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer
-
Ikeda, K.; Arase, Y.; Saitoh, S.; Kobayashi, M.; Suzuki, Y.; Suzuki, F.; Tsubota, A.; Chayama, K.; Murashima, N.; Kumada, H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000, 32, 228–232. [CrossRef] [PubMed]
-
(2000)
Hepatology
, vol.32
, pp. 228-232
-
-
Ikeda, K.1
Arase, Y.2
Saitoh, S.3
Kobayashi, M.4
Suzuki, Y.5
Suzuki, F.6
Tsubota, A.7
Chayama, K.8
Murashima, N.9
Kumada, H.10
-
177
-
-
0037080269
-
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches
-
Sakon, M.; Nagano, H.; Dono, K.; Nakamori, S.; Umeshita, K.; Yamada, A.; Kawata, S.; Imai, Y.; Iijima, S.; Monden, M. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002, 94, 435–442. [CrossRef] [PubMed]
-
(2002)
Cancer
, vol.94
, pp. 435-442
-
-
Sakon, M.1
Nagano, H.2
Dono, K.3
Nakamori, S.4
Umeshita, K.5
Yamada, A.6
Kawata, S.7
Imai, Y.8
Iijima, S.9
Monden, M.10
-
178
-
-
0035872948
-
Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial
-
Kubo, S.; Nishiguchi, S.; Hirohashi, K.; Tanaka, H.; Shuto, T.; Yamazaki, O.; Shiomi, S.; Tamori, A.; Oka, H.; Igawa, S.; et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann. Intern. Med. 2001, 134, 963–967. [CrossRef] [PubMed]
-
(2001)
Ann. Intern. Med.
, vol.134
, pp. 963-967
-
-
Kubo, S.1
Nishiguchi, S.2
Hirohashi, K.3
Tanaka, H.4
Shuto, T.5
Yamazaki, O.6
Shiomi, S.7
Tamori, A.8
Oka, H.9
Igawa, S.10
-
179
-
-
18644381723
-
Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma
-
Reinisch, W.; Holub, M.; Katz, A.; Herneth, A.; Lichtenberger, C.; Schoniger-Hekele, M.; Waldhoer, T.; Oberhuber, G.; Ferenci, P.; Gangl, A.; et al. Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma. J. Immunother. 2002, 25, 489–499. [CrossRef] [PubMed]
-
(2002)
J. Immunother.
, vol.25
, pp. 489-499
-
-
Reinisch, W.1
Holub, M.2
Katz, A.3
Herneth, A.4
Lichtenberger, C.5
Schoniger-Hekele, M.6
Waldhoer, T.7
Oberhuber, G.8
Ferenci, P.9
Gangl, A.10
-
180
-
-
0036274984
-
Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma
-
Palmieri, G.; Montella, L.; Milo, M.; Fiore, R.; Biondi, E.; Bianco, A.R.; Martignetti, A. Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma. Am. J. Clin. Oncol. 2002, 25, 224–226. [CrossRef] [PubMed]
-
(2002)
Am. J. Clin. Oncol.
, vol.25
, pp. 224-226
-
-
Palmieri, G.1
Montella, L.2
Milo, M.3
Fiore, R.4
Biondi, E.5
Bianco, A.R.6
Martignetti, A.7
-
181
-
-
84887427672
-
Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma
-
Cui, J.; Wang, N.; Zhao, H.; Jin, H.; Wang, G.; Niu, C.; Terunuma, H.; He, H.; Li, W. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int. J. Cancer 2014, 134, 342–351. [CrossRef] [PubMed]
-
(2014)
Int. J. Cancer
, vol.134
, pp. 342-351
-
-
Cui, J.1
Wang, N.2
Zhao, H.3
Jin, H.4
Wang, G.5
Niu, C.6
Terunuma, H.7
He, H.8
Li, W.9
-
182
-
-
84455162015
-
Hepatocellular carcinoma-specific immunotherapy with synthesized alpha1,3-galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells
-
Qiu, Y.; Xu, M.B.; Yun, M.M.; Wang, Y.Z.; Zhang, R.M.; Meng, X.K.; Ou-Yang, X.H.; Yun, S. Hepatocellular carcinoma-specific immunotherapy with synthesized alpha1,3-galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells. World J. Gastroenterol. 2011, 17, 5260–5266. [CrossRef] [PubMed]
-
(2011)
World J. Gastroenterol.
, vol.17
, pp. 5260-5266
-
-
Qiu, Y.1
Xu, M.B.2
Yun, M.M.3
Wang, Y.Z.4
Zhang, R.M.5
Meng, X.K.6
Ou-Yang, X.H.7
Yun, S.8
-
183
-
-
84979771531
-
Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma
-
Kamiya, T.; Chang, Y.H.; Campana, D. Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma. Cancer Immunol. Res. 2016, 4, 574–581. [CrossRef] [PubMed]
-
(2016)
Cancer Immunol. Res.
, vol.4
, pp. 574-581
-
-
Kamiya, T.1
Chang, Y.H.2
Campana, D.3
-
184
-
-
84863303647
-
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival
-
Sawada, Y.; Yoshikawa, T.; Nobuoka, D.; Shirakawa, H.; Kuronuma, T.; Motomura, Y.; Mizuno, S.; Ishii, H.; Nakachi, K.; Konishi, M.; et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. Clin. Cancer Res. 2012, 18, 3686–3696. [CrossRef] [PubMed]
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 3686-3696
-
-
Sawada, Y.1
Yoshikawa, T.2
Nobuoka, D.3
Shirakawa, H.4
Kuronuma, T.5
Motomura, Y.6
Mizuno, S.7
Ishii, H.8
Nakachi, K.9
Konishi, M.10
-
185
-
-
84922713971
-
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
-
Voron, T.; Colussi, O.; Marcheteau, E.; Pernot, S.; Nizard, M.; Pointet, A.L.; Latreche, S.; Bergaya, S.; Benhamouda, N.; Tanchot, C.; et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 2015, 212, 139–148. [CrossRef] [PubMed]
-
(2015)
J. Exp. Med.
, vol.212
, pp. 139-148
-
-
Voron, T.1
Colussi, O.2
Marcheteau, E.3
Pernot, S.4
Nizard, M.5
Pointet, A.L.6
Latreche, S.7
Bergaya, S.8
Benhamouda, N.9
Tanchot, C.10
-
186
-
-
84899978058
-
Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma
-
Chan, A.W.; Tong, J.H.; Chan, S.L.; Lai, P.B.; To, K.F. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology 2014, 64, 935–950. [CrossRef] [PubMed]
-
(2014)
Histopathology
, vol.64
, pp. 935-950
-
-
Chan, A.W.1
Tong, J.H.2
Chan, S.L.3
Lai, P.B.4
To, K.F.5
-
187
-
-
79953059789
-
Natural innate and adaptive immunity to cancer
-
Vesely, M.D.; Kershaw, M.H.; Schreiber, R.D.; Smyth, M.J. Natural innate and adaptive immunity to cancer. Ann. Rev. Immunol. 2011, 29, 235–271. [CrossRef] [PubMed]
-
(2011)
Ann. Rev. Immunol.
, vol.29
, pp. 235-271
-
-
Vesely, M.D.1
Kershaw, M.H.2
Schreiber, R.D.3
Smyth, M.J.4
-
188
-
-
0036669785
-
The interaction properties of costimulatory molecules revisited
-
Collins, A.V.; Brodie, D.W.; Gilbert, R.J.; Iaboni, A.; Manso-Sancho, R.; Walse, B.; Stuart, D.I.; van der Merwe, P.A.; Davis, S.J. The interaction properties of costimulatory molecules revisited. Immunity 2002, 17, 201–210. [CrossRef]
-
(2002)
Immunity
, vol.17
, pp. 201-210
-
-
Collins, A.V.1
Brodie, D.W.2
Gilbert, R.J.3
Iaboni, A.4
Manso-Sancho, R.5
Walse, B.6
Stuart, D.I.7
van der Merwe, P.A.8
Davis, S.J.9
-
189
-
-
85007494451
-
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
-
Duffy, A.G.; Ulahannan, S.V.; Makorova-Rusher, O.; Rahma, O.; Wedemeyer, H.; Pratt, D.; Davis, J.L.; Hughes, M.S.; Heller, T.; ElGindi, M.; et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J. Hepatol. 2017, 66, 545–551. [CrossRef] [PubMed]
-
(2017)
J. Hepatol.
, vol.66
, pp. 545-551
-
-
Duffy, A.G.1
Ulahannan, S.V.2
Makorova-Rusher, O.3
Rahma, O.4
Wedemeyer, H.5
Pratt, D.6
Davis, J.L.7
Hughes, M.S.8
Heller, T.9
Elgindi, M.10
-
190
-
-
84884698526
-
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
-
Shi, L.; Chen, S.; Yang, L.; Li, Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J. Hematol. Oncol. 2013, 6, 74. [CrossRef] [PubMed]
-
(2013)
J. Hematol. Oncol.
, vol.6
, pp. 74
-
-
Shi, L.1
Chen, S.2
Yang, L.3
Li, Y.4
-
191
-
-
84901985040
-
The PD-1/PD-Ls pathway and autoimmune diseases
-
Dai, S.; Jia, R.; Zhang, X.; Fang, Q.; Huang, L. The PD-1/PD-Ls pathway and autoimmune diseases. Cell. Immunol. 2014, 290, 72–79. [CrossRef] [PubMed]
-
(2014)
Cell. Immunol.
, vol.290
, pp. 72-79
-
-
Dai, S.1
Jia, R.2
Zhang, X.3
Fang, Q.4
Huang, L.5
-
192
-
-
84951126341
-
Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer
-
Hamanishi, J.; Mandai, M.; Ikeda, T.; Minami, M.; Kawaguchi, A.; Murayama, T.; Kanai, M.; Mori, Y.; Matsumoto, S.; Chikuma, S.; et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 2015, 33, 4015–4022. [CrossRef] [PubMed]
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 4015-4022
-
-
Hamanishi, J.1
Mandai, M.2
Ikeda, T.3
Minami, M.4
Kawaguchi, A.5
Murayama, T.6
Kanai, M.7
Mori, Y.8
Matsumoto, S.9
Chikuma, S.10
-
193
-
-
85018660134
-
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial
-
El-Khoueiry, A.B.; Sangro, B.; Yau, T.; Crocenzi, T.S.; Kudo, M.; Hsu, C.; Kim, T.Y.; Choo, S.P.; Trojan, J.; Welling, T.H.R.; et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017, 389, 2492–2502. [CrossRef]
-
(2017)
Lancet
, vol.389
, pp. 2492-2502
-
-
El-Khoueiry, A.B.1
Sangro, B.2
Yau, T.3
Crocenzi, T.S.4
Kudo, M.5
Hsu, C.6
Kim, T.Y.7
Choo, S.P.8
Trojan, J.9
Welling, T.H.R.10
-
194
-
-
0037126021
-
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
-
Iwai, Y.; Ishida, M.; Tanaka, Y.; Okazaki, T.; Honjo, T.; Minato, N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 2002, 99, 12293–12297. [CrossRef] [PubMed]
-
(2002)
Proc. Natl. Acad. Sci. USA
, vol.99
, pp. 12293-12297
-
-
Iwai, Y.1
Ishida, M.2
Tanaka, Y.3
Okazaki, T.4
Honjo, T.5
Minato, N.6
-
195
-
-
85018630883
-
Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells
-
Zhong, F.; Cheng, X.; Sun, S.; Zhou, J. Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells. Oncol. Rep. 2017, 37, 3061–3067. [CrossRef] [PubMed]
-
(2017)
Oncol. Rep.
, vol.37
, pp. 3061-3067
-
-
Zhong, F.1
Cheng, X.2
Sun, S.3
Zhou, J.4
-
196
-
-
85022010830
-
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
-
Liu, J.; Liu, Y.; Meng, L.; Liu, K.; Ji, B. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol. Rep. 2017, 38, 899–907. [CrossRef] [PubMed]
-
(2017)
Oncol. Rep.
, vol.38
, pp. 899-907
-
-
Liu, J.1
Liu, Y.2
Meng, L.3
Liu, K.4
Ji, B.5
-
197
-
-
52349124048
-
Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice
-
Zhang, W.; Liu, J.; Wu, Y.; Xiao, F.; Wang, Y.; Wang, R.; Yang, H.; Wang, G.; Yang, J.; Deng, H.; et al. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice. Biochem. Biophys. Res. Commun. 2008, 376, 10–14. [CrossRef] [PubMed]
-
(2008)
Biochem. Biophys. Res. Commun.
, vol.376
, pp. 10-14
-
-
Zhang, W.1
Liu, J.2
Wu, Y.3
Xiao, F.4
Wang, Y.5
Wang, R.6
Yang, H.7
Wang, G.8
Yang, J.9
Deng, H.10
-
198
-
-
84975807216
-
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
-
Sawada, Y.; Yoshikawa, T.; Ofuji, K.; Yoshimura, M.; Tsuchiya, N.; Takahashi, M.; Nobuoka, D.; Gotohda, N.; Takahashi, S.; Kato, Y.; et al. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunol. 2016, 5, e1129483. [CrossRef] [PubMed]
-
(2016)
Oncoimmunol
, vol.5
-
-
Sawada, Y.1
Yoshikawa, T.2
Ofuji, K.3
Yoshimura, M.4
Tsuchiya, N.5
Takahashi, M.6
Nobuoka, D.7
Gotohda, N.8
Takahashi, S.9
Kato, Y.10
-
199
-
-
84940532471
-
Dendritic-tumor fusion cells in cancer immunotherapy
-
PubMed
-
Takakura, K.; Kajihara, M.; Ito, Z.; Ohkusa, T.; Gong, J.; Koido, S. Dendritic-tumor fusion cells in cancer immunotherapy. Discov. Med. 2015, 19, 169–174. [PubMed]
-
(2015)
Discov. Med.
, vol.19
, pp. 169-174
-
-
Takakura, K.1
Kajihara, M.2
Ito, Z.3
Ohkusa, T.4
Gong, J.5
Koido, S.6
-
200
-
-
85019622453
-
Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma
-
Zhao, T.; Jia, H.; Cheng, Q.; Xiao, Y.; Li, M.; Ren, W.; Li, C.; Feng, Y.; Feng, Z.; Wang, H.; et al. Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma. Oncol. Rep. 2017, 37, 3405–3414. [CrossRef] [PubMed]
-
(2017)
Oncol. Rep.
, vol.37
, pp. 3405-3414
-
-
Zhao, T.1
Jia, H.2
Cheng, Q.3
Xiao, Y.4
Li, M.5
Ren, W.6
Li, C.7
Feng, Y.8
Feng, Z.9
Wang, H.10
-
201
-
-
84928827745
-
Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma
-
Wang, X.; Bayer, M.E.; Chen, X.; Fredrickson, C.; Cornforth, A.N.; Liang, G.; Cannon, J.; He, J.; Fu, Q.; Liu, J.; et al. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J. Surg. Oncol. 2015, 111, 862–867. [CrossRef] [PubMed]
-
(2015)
J. Surg. Oncol.
, vol.111
, pp. 862-867
-
-
Wang, X.1
Bayer, M.E.2
Chen, X.3
Fredrickson, C.4
Cornforth, A.N.5
Liang, G.6
Cannon, J.7
He, J.8
Fu, Q.9
Liu, J.10
-
202
-
-
85049144136
-
Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma
-
Brown, Z.J.; Yu, S.J.; Heinrich, B.; Ma, C.; Fu, Q.; Sandhu, M.; Agdashian, D.; Zhang, Q.; Korangy, F.; Greten, T.F. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunol. Immunother. 2018, 67, 1305–1315. [CrossRef] [PubMed]
-
(2018)
Cancer Immunol. Immunother.
, vol.67
, pp. 1305-1315
-
-
Brown, Z.J.1
Yu, S.J.2
Heinrich, B.3
Ma, C.4
Fu, Q.5
Sandhu, M.6
Agdashian, D.7
Zhang, Q.8
Korangy, F.9
Greten, T.F.10
|